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ABSTRACT 
Transferrin receptor (TfR) appears on activated T cells following 
interaction of the antigen-major histocompatibility complex (MHC) with the T 
cell receptor (TCR) and the resulting expression of IL-2 receptor (IL-2R). 
Previous work in the laboratory has demonstrated allograft prolongation 
following administration of anti-TfR monoclonal antibody (mAb). Studies in the 
area of cancer immunotherapy have shown that TfR blockade and modulation 
deprives the tumor of iron, which is essential for continued growth and 
proliferation, while TfR modulation results in poor T cell proliferation, 
respectively. This dissertation focuses on the hypothesis that modulation ofT 
cell TfR expression is associated with altered T cell responses to alloantigen. 
The studies presented here explored the immunosuppressive effects of anti-
TfR mAb in experimental transplantation. U sing heterotopic, nonvascularized 
cardiac allograft and cell-mediated immunity models, anti-TfR mAb was 
demonstrated to be a' potent immunosuppressant in prolonging cardiac 
allograft survival and altering T cell responses to alloantigen. Enhanced 
cardiac allograft survival was achieved by simultaneous blockade of TfR and 
IL .. 2R. The possible mechanisms responsible for this allograft prolongation 
and suppressed T cell responses include alterations in T cell surface receptors, 
shifts in the intragraft cytokine profiles, and modulation in signaling pathways. 
TfR modulation in association with the immunosuppressive effects of DST was 
demonstrated by a decrease in TfR expression that paralleled early CTL 
suppression. In addition, TfR modulation was observed following delivery of 
XlV 
anti-CD3 mAb or anti-TfR mAb in combination with anti-IL-2R mAb. The 
induction of TfR expression appeared to be independent of CD28 and IL-2R 
signaling, while CD3 signaling was involved in the promotion ofTfR expression. 
The novel blockade of TfR, alone or in combination with blockade of IL-2R, in 
transplant and cell-mediated immunity models have provided additional 






TfR, a 180 kDa disulfide-linked transmembrane glycoprotein, is a ~dely­
distributed cell surface receptor present on rapidly proliferating and 
differentiated quiescent cells. TfR is essential for the continued growth of 
proliferating cells and is closely linked to proliferative status (1-3). TfR is 
highly expressed on rapidly proliferating normal cells, on transformed cells, and 
on specialized nondividing cells, such as reticulocytes, which have high 
requirements for iron (2). Furthermore, surface expression ofTfR is decreased 
or absent on quiescent, nonproliferating and differentiated cells (2). One 
function of TfR is to bind transferrin, the major serum iron transporter. The 
receptor has the capacity to bind one or two molecules of transferrin with 
preferential binding of the iron-saturated molecule (3). Cellular iron uptake is 
mediated by TfR-mediated endocytosis, a process required for cell proliferation 
(4, 5). 
Iron Metabolism 
All living things require iron for growth and survival. Iron plays a role in 
the activation of molecular oxygen, reduction of ribonucleotides, activation and 
decomposition of peroxides, electron transport, and proliferation (6). In the 
stomach, iron is solubilized at the low pH of the gastric secretions and binds to 
mucin. The mucin-iron complex is absorbed in the duodenum where it can be 
transported across the basolateral membrane to the blood or stored in the cell 
as ferritin. In the blood, iron is transported by the serum protein, transferrin 
(7). 
Transferrin, a 80 kDa class of iron transport glycoptoteins with low and 
high affinity binding sites, has been isolated from the serum, mucosa, ova, 
testicles, and the Central Nervous System. The function of transferrin, which 
3 
has been well characterized, is essential for proper distribution of absorbed iron 
to the tissues. Iron can be absorbed in the absence of transferrin, however, the 
plasma transferrin supply most of the body tissues with iron, while the other 
transferrins are produced locally in areas not reached by the plasma. The 
principal site for plasma transferrin is in the liver with production in the 
hepatocytes. The lactating mammary gland is another major site of 
transferrin production which exceeds the liver. The iron status of transferrin 
has an important role in the binding capacity of the TfR. Diferric transferrin 
has the greatest affinity, monoferric transferrin has an intennediate affinity, 
and apotransferrin has a low affinity for TfR at the physiological pH of 7.4 (3, 
7). 
Binding of transferrin to its receptor followed is by receptor-mediated 
endocytosis, with accumulation of transferrin within endocytotic vesicles or 
endosomes. Subsequently, these vesicles undergo an acidification process that 
leads to the dissociation of iron from transferrin. Finally, the transferrin-
receptor complex is shuttled back to the surface where transferrin is released, 
leaving the receptor available for additional cycles of endocytosis (2, 8-10) 
(Figure 1-1). 
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Figure 1·1. Iron transport by transferrin:transferrin receptor 
endocytosis. Modified from Qian Z. et al., Biochimica et Biophysica Acta 
1995, 1269: 205 (11). 
Regulation of Transferrin Receptor Expression 
Reticulocytes and rapidly proliferating cells respond to their metabolic 
needs for iron by varying the number of TfRs. TfR expression is modulated via 
intracellular iron concentration through a negative feedback mechanism at the 
level of translational control by an iron-responsive element (IRE), a stem-loop 
structure located in the 3' untranslated region of the mRNA (7, 12, 13). At low 
intracellular iron levels, the activation of iron-regulatory protein (IRP) occurs 
through a conformational change that permits binding of the IRP to the IRE, 
protecting the TfR mRNA from degradation. In addition, mRNAs for ferritin 
and erythroid 5-aminolaevulinic acid synthase (E-ALAS), important proteins 
involved in iron storage and heme biosynthesis, contain the IRE. However, the 
stem-loop located in the 5' untranslated region of these mRNAs blocks the 
translation of ferritin and E-ALAS when the IRE is bound by the IRP (7, 12-14) 
(Figure 1-2). 
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In addition to regulation by intracellular iron content, nitric oxide (NO) 
also activates the IRP-binding activity in macrophages and monocytes (13, 
15). Nitric oxide is a central component of macrophage-mediated cytotoxicity 
in mammals. It is generated after stimulation of macrophages with interferon 
gamma (INF-y), tumor necrosis factor alpha (TNF-a), and IL-1. Since nitric 
oxide induces a conformational change in IRP, increased NO production leads 
to increased TfR expression by binding of IRP, thereby protecting TfR mRNA 
from degradation. Increased intracellular iron leads to an eventual increase in 
ferritin expression and iron storage (Figure 1-2). This not only satisfies the 
metabolic requirements of the cell, but also results in a limitation of iron 
availability for invading microorganisms (13, 15). 
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Figure 1·2. Effects of iron and nitric oxide on transferrin receptor 
expression. Transferrin receptor, ferritin, and e-ALAS expression change 
with levels of intracellular iron and nitric oxide. IRE = iron responsive element. 
IRP = iron-regulatory protein. NO = nitric oxide. Modified from Weiss G. et al., 
Immunology Today 1995, 16: 495 (15). 
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Role of Transferrin Receptor in T Cell Actiyation 
In addition to its crucial role in iron uptake, TfR is involved in T cell 
activation, a two-signal process. The primary signal is provided by the 
interaction of the TCR with an antigen complexed to the MHC class I or class 
lIon an antigen-presenting cell (16, 17). The interaction between the T cell 
and the antigen-presenting cell initiates a cascade of biochemical events. The 
primary signal initiated by the TCR leads to progression of the T cell from the 
GO to the G1 phase of the cell cycle, and is calcium-dependent (18). Signaling 
through the TCR alone can lead to antigen desensitization, T cell anergy, or T 
cell death. The costimulatory or secondary signal is provided by a co-receptor-
ligand interaction (19, 20). In some cases, this interaction is mediated through 
the CD28 receptor on T cells (21-25). The ligands for CD28, B7-1 and B7-2, 
are located on antigen-presenting cells (25-27). The second signal causes 
progression of the T cell from the Gl to the S phase of the cell cycle and is 
characterized as calcium-independent (18). Only when both signals through 
the TCR and the costimulatory receptor are received does this process result 
in proliferation, IL-2 production, and other effector functions. The expression of 
the IL-2R is up-regulated following T cell activation (16, 20) and is necessary 
for IL-2 to bind and to assist in T-cell proliferation (2). IL ... 2 and IL-2R form an 
autocrine loop, with the expression of IL-2R allowing the T cell to progress from 
the Gl to the S phase of the cell cycle (12, 18). 
TfR expression also increases following T cell activation (4, 14, 28). The 
increased expression of TfR is detected only after IL-2R expression in a 
sequence necessary for initiating T cell proliferation in quiescent cells. 
Blockade of TfR inhibits entry into the S phase of the cell cycle, interrupts 
DNA synthesis, and abrogates T cell proliferation (12, 28). However, the role 
7 
of TfR in T cell activation remains to be defined. Salmeron et ale demonstrated 
that antibodies to TfR induced tyrosine phosphorylation in cells expressing the 
TCR, but not in cells lacking TCR expression (29). In addition, TfR was found 
to be physically associated with the eD3 zeta-chain and with the tyrosine 
kinase, ZAP70 (29). These findings suggest that the CD3 zeta-chain may be 
responsible for transducing transferrin-induced signals. 
In T cell activation, mRNAs for IL-2R, IL-2, and TfR are induced 
sequentially. Greater than 80% of the T cells stimulated with 
phytohemagglutinin (PHA) and phorbol esters express surface IL-2R within 24 
hours. TfR expression does not appear until 48 hours after stimulation (1, 28). 
Another study using flow cytometry revealed that after 48 hours, 51% of the T 
cells stimulated with mitogen express both IL-2R and TfR, 40% express only 
IL-2R, and 9% express neither receptor (5). The addition of IL-2R blocking 
mAbs results in abrogation of both IL-2R and TfR expression with cells 
remaining in the GO to G1 phase of the cell cycle (1, 28). These data suggest 
that IL-2R expression is a prerequisite for TfR expression. However, the 
mechanisms underlying TfR gene expression in T cells have not been clearly 
defined. 
Tumor-Infiltratine- Lymphocytes and Transferrin Receptor Expression 
It has been suggested that the tissue environment may adversely 
influence TfR expression in T cells. Kudoh et ale demonstrated that tumor 
infiltrating lymphocytes (TILs) from patients with renal cell carcinoma fail to 
express TfR and exhibit poor proliferative responses (30). In contrast, 
peripheral blood lymphocytes (PBLs) from the same patients demonstrate no 
defect in TfR expression and display a strong proliferative response (30). This 
lack of TfR expression in TILs seems to be specific, since there are no 
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detectable changes in the expression of the IL-2 receptor alpha chain (IL-2Ra) 
in these cells (30). In addition, TILs from patients with renal cell carcinoma 
were found to be deficient in the expression of the CD3 zeta-chain and of the 
protein tyrosine kinases, p56lck and p59fyn (31). Thus, it is not clear whether 
reduced expression of the TfR may be the cause or the result of altered 
expression of these proteins involved in TCR signaling. 
Relevant Immunosuppressive Ree}mens 
Current immunosuppressants that are being used clinically and 
experimentally to achieve immune hyporesponsiveness following 
transplantation function through a variety of known and unknown 
mechanisms. Some of the more common and well characterized of these 
immunosuppressants include blood transfusion, anti-CD3 mAb, CTLA4Ig, and 
anti-IL-2R mAh. These agents interrupt signals that occur prior to the 
expression of TfR during T cell activation. Modification of TfR expression by 
these immunosuppressants may be contributing to the suppressed immune 
state during transplantation and needs to be further defined. 
Anti-CD3 monoclonal antibodies: The TCR is noncovalantly associated 
with the nonpolymorphic multi-chain complex, CD3. CD3 consists of at least 
five protein subunits or chains referred to as ,,(, 0, E, and ~ homodimer (32-34). 
The T cell receptor chains have shorter cytoplasmic tails of approximately 5 
amino acids. These shorter receptor chains and the longer cytoplasmic tails of 
the CD3 complex suggest that the CD3 complex is responsible for TCR/CD3-
induced signaling (35). The TCR/CD3 complex is involved in antigen-specific T 
cell responses including cytotoxic T lymphocyte (CTL) function. CTLs 
eliminate cells expressing viral and tumor antigens. In addition, allogeneic cells 
are potent inducers and targets of CTLs (33). The in vivo administration of 
9 
anti-CD3 monoclonal antibody prolongs allograft survival in humans as well as 
experimental animal models (36, 37). OKT3 anti-CD3 monoclonal antibody, 
currently being used clinically, achieves immunosuppression through the 
generation of CD3-negative T cells (38). 
CTLA4Ie-: T cell activation requires signaling through a costimulatory 
pathway such as CD 28/B7 . CTLA4, a cell surface receptor with structural 
homology to CD28, is expressed on activated T cells with peak expression 48 
hours after T cell activation (39-41). CTLA4 has recently been found to be a 
potential negative regulator of T cell activation (42-45). CD28 and CTLA4 
bind the ligands B7-1 and B7-2, which are expressed on antigen presenting cells 
(25-27,46, 47). However, CTLA4 binds B7-1 and B7-2 with 20 times higher 
avidity than CD28 (39), making CTLA4 ia potential inhibitor of CD28/B7 
binding. The fusion protein CTLA4Ig inhibits CD28 binding with B7-1 and B7-
2 and has been shown to inhibit in vitro and in vivo alloantigen-specific T cell 
responses (48, 49). In addition, by blocking the CD28 costimulatory pathway, 
CTLA4Ig can prolong allograft survival and alter cell-mediated immunity (48-
51). 
Donor-Specific Blood Transfusions: Clinically, blood transfusions have 
been shown to lead to a decrease in both the number and function of 
lymphocytes (52). Many investigators have shown that the administration of 
donor-specific blood transfusions (DST) prior to transplantation results in 
allograft prolongation in humans as well as in experimental animal models (52-
57). Wood et ale demonstrated that rats receiving a single DST 14 days prior to 
a cardiac allograft transplantation were able to overcome chronic rejection 
episodes, a common barrier to long-term allograft survival (57). DSTs have 
been shown to act synergistically with the routinely used immunosuppressive 
agents cyclosporine A and FK506 (58, 59). The mechanisms responsible for 
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allograft prolongation with DST are largely unknown. van Twuyver et ale 
demonstrated that DST with one HLA haplotype match resulted in CTL 
unresponsiveness in patients awaiting renal transplantation (60, 61). It has 
also been suggested that DSTs promote the production of T helper 2 cytokines 
while hindering T helper 1 cytokine production (55, 62, 63). In addition, DSTs 
were found to induce a selective decrease in the use of certain TCR V(3 families 
(61). 
Clinical Transplantation 
Clinical transplantation currently utilizes continuous systemic 
immunosuppression through various available immunosuppressive regimens, 
which include steroids, cyclosporin A, FK506, and OKT3. These agents result 
in global suppression of lymphocyte proliferation, lymphokine production, and 
inflammatory responses ultimately leading to graft rejection, an increased 
incidence of infection, and malignancies. The primary goal in clinical 
transplantation is to achieve antigen-specific immunosuppression without 
adverse side effects by targeting only the immune cells responding to the 
transplanted alloantigens, while leaving the remaining cells intact. This 
concept makes TfR, which appears only after T cell activation, an ideal target. 
Experimental Transplant Model 
To begin addressing the efficacy ofTfR as a target in transplantation, a 
murine heterotopic, nonvascularized cardiac allograft model was utilized, which 
is a relatively simple technique to study allograft survival in vivo. In this 
model, donor, neonatal mouse hearts are placed subcutaneously in the ear 
pinnae of adult recipients with survival of the allograft is being determined by 
EKG monitoring. This model allows for EL quantitative and objective 
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measurement for allograft survival and function and allows for the study of 
immunological interactions between the graft and the host. 
Specific Aim I of this dissertation determined the effect of anti-TfR mAb 
on allograft survival. The mAb utilized in these studies binds to the TfR 
epitope involved in T cell activation, failing to interfere with iron uptake in 
proliferating T cells. Therefore, the mAb allows examination of the roles ofTfR 
that are independent of iron absorption. A heterotopic, nonvascularized cardiac 
allograft model assessed allograft prolongation in mice treated with anti-TfR 
mAb. Dose-response and time course experiments were performed to 
determine the optimal time for achieving maximum immunosuppression with 
anti-TfR mAb. Alterations in T cell function were assessed using cytotoxic and 
mixed lymphocyte response assays. 
Specific Aim II of this dissertation explored the modulation of TfR 
expression during altered T cell responses. Modulation ofT cell TfR in vivo and 
in vitro following exposure to immunosuppressants including anti-TfR mAb, 
anti-CD3 mAb, CTLA4Ig, or blood transfusions were evaluated using flow 
cytometry and semi-quantitative reverse transcriptase polymerase chain 
reaction (RT-PCR). Exposure to these immunosuppressants allow for the 
assessment of differential TfR expression during altered T cell responses. 
Specific Aim III of this dissertation delineated the mechanisms 
responsible for prolonged allograft survival and altered T cell responses to 
alloantigen by anti-TfR mAh. Disruptions in the association of TfR with CD3 
zeta-chain and ZAP70, alterations in the cytokine micro-environment, and 
modulation in expression of cell surface receptors important in T cell activation 
were evaluated as the possible mechanisms responsible for 
immunosuppression generated by anti-TfR mAb. 
CHAPTER 2 
MATERIALS AND METHODS 
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Animals: Female CBAlJ (H-2k), C57BL/6J (H-2b), and BALB/c ByJ (H-2d) 
mice (7-8 weeks of age) were purchased from Jackson Laboratory (Bar 
Harbor, ME). Timed .. pregnant C57BL/6 were purchased from Jackson 
Laboratory or generated in the laboratory. 
Anesthesia: Surgical procedures were performed using general anesthesia. 
Mice were given 0.01 to 0.02 mg of Prom ace (Aveco, Fort Dodge, Iowa) and 1 to 
2 mg of Ketastat (Fort Dodge Laboratories, Fort Dodge, Iowa) per 10 grams 
body weight in tissue grade water. 
Reaients: The R17 217.1.3 rat IgG2a anti-mouse TfR hybrldoma, a gift from 
Dr. J. Lesley (San Diego, CA), the 145-2C11 hamster IgG anti-mouse CD3 
hybridoma, a gift from Dr. J. A. Bluestone (Chicago, IL); the 3C7 rat IgG anti-
mouse IL-2R hybridoma, a gift from Dr. E. Shevach (Bethesda, MD); the 
HRa4 hamster IgG anti-mouse hybridoma, a gift from Dr. H. Yagita (Tokyo, 
Japan) and the 12-15 rat IgGl anti-mouse CD2 hybridoma, a gift from Dr. P. 
Altevolt (Heidelberg, Gennany) were grown in culture and purified with protein 
G affinity columns. The human CTLA4Ig and control L6 fusion proteins were 
a gift from Dr. P. Linsley (Seattle, WA). 
Cardiac Transplantation: Donor neonatal C57BL/6 mice were sacrificed. 
Whole hearts were removed and placed into subcutaneous pockets in the ear 
pinnae of adult CBAlJ recipients as previously described (64, 65). Survival of 
the allografts was followed by EKG monitoring (Grass Instruments, Polygraph 
78 series with preamplifer and filters) every other day. Rejection was 
determined by lack of cardiac activity for 3 consecutive readings. Statistical 
significance was determined by the Wilcoxon Rank Sum. Recipients received 
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intravenous injections of anti-TfR and/or anti-IL-2R or isotype control mAbs at 
the indicated dose in 0.5 ml of phosphate-buffered saline (PBS) at the specified 
time after grafting. 
Donor-specific blood transfusions: Freshly isolated, whole donor CBAlJ or 
C57BL/6 blood was obtained by carotid section and collected into heparinized 
eppendorftubes at a final concentration ofO.IOO ml heparinlml of whole blood. 
CBAlJ recipients received intravenous injections ofO.20D ml of freshly isolated 
whole heparinized autologous (CBAlJ) or donor C57BU6 blood (63). Control 
animals received intravenous injections of 0.200 ml of heparinized saline. 
Recipients were sacrificed on days 3, 4, and 5 post-transfusion. Splenocytes 
are prepared and used for CTL responsiveness, mixed lymphocyte responses, 
and flow cytometry. 
Alloanti~en-specific Cytotoxic T lymphocytes: Spleens from naive CBAlJ, 
allograft recipients 7 days post-transplantation, or from transfused CBAlJ, 
were removed and gently dissociated into a single cell suspensions. Red blood 
cells were removed from the responder (eBA) and stimulator (C57BL/6J or 
BALB/c ByJ) cell populations by Tris-NH4Cllysis. The CTL culture and 
assays were performed as previously described (66). A standard 4-hour Cr51 
release assay was performed using EL-4 (H-2b) or P815 (H-2d) as targets. 
Controls included irrelevant CCL1.3 (H-2k) targets and were ~ 5% specific 
lysis. Spontaneous release showed 5-15% of total incorporated counts. CTL 
generated were CD8+, H-2 restricted, and alloantigen-specific with peak 
primary CTL responses noted after 7 days of culture. Results are expressed 
as: 
specific lysis = <ex:gerimental - s:gontaneous) + SEM 
(100% lysis - spontaneous) 
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The standard error of the mean (SEM) was always ~ 2%. Statistical 
significance for the CTL assay was analyzed with Student's two tailed t-test. 
Mixed Lymphocyte Res:gonses: Responder splenocytes (2 x 105 ) were 
cocultured with 2 x 105 1500 rad ,),-irradiated C57BL/6 or BALB/c ByJ 
stimulator cells in triplicate for 3-7 days. The wells were pulsed with 0.5 IlCi of 
H3-thymidine 18 hours prior to termination of the culture, harvested onto 
glass fiber filters, and incorporation quantitated on a scintillation counter. 
Results are expressed as mean + SEM. Statistical significance was performed 
using Student's two tailed t-test (65). 
In vitro allo~eneic cultures: CBNJ and C57BU6 spleens were removed and 
gently dissociated into single cell suspensions. Red blood cells were removed by 
Tris-NH4Cllysis. Responder CBNJ (7 x 106 cells) were co-cultured with 6 x 
106 ,),-irradiated (1500 rads) C57BL/6 stimulators. At the initiation of culture, 
anti-TfR or isotype-matched control mAbs were added at 5 Ilg/ml. After 24 
hours in culture, the cells were harvested and RNA isolated for the 
examination of cytokine mRNA expression. 
Natural Killer Assay: Spleens from naive CBNJ or allograft recipients 7 days 
post-transplantation were removed and gently dissociated into single cell 
suspensions. Red blood cells were removed by Tris-NH4Cllysis. Non-adherent 
cells were eliminated from effectors (1.5 x 108 cells) using nylon wool 
(Polyscience Inc., Warrington, PA) purification columns. T cells were 
eliminated from the remaining cells by incubating the cells with a mixture of 
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145-2Cl1 hamster anti-mouse CD3, GKl.5 rat anti-mouse CD4, and CT-
CDSa rat anti-mouse CDS for 30 minutes at 4QC. Following antibody 
treatment, cells were treated with rabbit complement (1:6) (Cedarlane 
Laboratories Limited, Hornby, Ontario, Canada) for 45 minutes at 37QC. NK 
cells were used at the indicated effector:target ratios in a 4 hour Cr51-release 
assay against NK-sensitive YAC (American Type Culture Collection, 
Rockville, MD) and NK-resistant CCLl.3 targets. Details of the assay are the 
same as described above for the CTL. 
Flow Cytometry: Cell washes and antibody dilutions were performed at 4QC in 
PBS containing 1% bovine serum albumin (BSA). TfR was stained with FITC-
R17 217.1.3 rat anti-mouse TfR mAb (1:100), CD3 with FITC-145-2Cll 
hamster anti-mouse CD3 mAb (1:100), and B7 with FITC-CTLA4Ig. IL-2R 
was stained with either 3C7 rat anti-mouse IL-2R mAb (50 Jlg/ml) followed by 
PE F(ab')2 goat anti-rat IgG (H+L) (TAGO Immunologicals, Inc., Burlington, 
CA) or with PE-3C7 (Pharmingen, San Diego, CA). Negative controls were 
either FITC F(ab')2 goat anti-rat IgG (H+L), PE F(ab')2 goat anti-rat IgG 
(H+L) antibody, PE rat IgG2b, or Tri-Color hamster IgG. CD2 was stained with 
Biotin-12-15 (1:30) followed by PE-SA (1:100) (TAGO Immunologicals, Inc., 
Burlington, CA). CD4 was stained with either FITC-rat anti-mouse CD4 or 
PE-rat anti-mouse CD4 (1:30), CD8 with FITC-rat anti-mouse CD8 (1:30), and 
CD28 with Tri-Color-hamster anti-mouse CD2S (1:30) (Caltag, Burlingame, 
CA). Flow cytometric analysis was performed using a Coulter Epics Elite with 
Elite Work Station software (Hialeah, FL). Results are expressed as the 
percent of cells staining above background. 
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Co-Localization: EL-4 cells were incubated with R17 217.1.3 rat anti-mouse 
TfR mAb (1:50) followed by FITC F(ab')2 goat anti-rat IgG (H+L) (1:100) 
(TAGO Immunologicals, Inc., Burlington, CA). TfR capping was induced by 
incubating the labeled cells at 37°C for 9 minutes. Subsequently, cells were 
fixed with 3% paraformaldehyde for 7 minutes and penneabilized with 0.1% 
saponin for 20 minutes. The fixed cells were incubated with rabbit anti-mouse 
ZAP70 polyclonal antibody (1:50) (Santa Cruz Biotechnology, Santa Cruz, CA) 
followed by rhodamine donkey anti-rabbit IgG (H + L) (1:100) (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) (67). The cells were 
viewed with an epiflourescence microscope and video captured using ImagePro 
Plus software (Media Cybernetics, Maryland). 
Co-Immunoprecipitation: EL-4 cells (3 xl07) were stimulated in culture with 
plate-bound 145-2C11 hamster IgG anti-mouse anti-CD3 monoclonal antibody 
(10 Ilg/ml) in the presence or absence ofR17 217.1.3 rat IgG2a anti-mouse TfR 
mAb (5 Jlg/ml) for 15 minutes. Following stimulation, the cells were lysed. The 
supernatants were precleared with 5 Jlg normal mouse immunoglobulin (Pierce, 
Rockford, IL) and 20 III protein A/G PL US-Agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA). TfR was immunoprecipitated using mouse 
anti-rat TfR mAb (2 Ilg/1xl0 6 cells) (Pharmingen, San Diego, CA). 
Immunoprecipitated proteins were resolved by SDS-PAGE, electrophoretically 
transferred to PVDF membrane, and blocked with 5% BSA for 2 hours. 
Subsequently, the blots were hybridized with anti-mouse TfR mAb (1:1000), 
mouse anti-mouse CD3 zeta-chain mAb (1:1000) (Pharmingen, San Diego, 
CA), or mouse anti-human ZAP70 (1:1500) (Transduction Laboratories, 
Lexington, KY) for one hour. The blots were washed with 0.05% Tween-20 in 
PBS. Finally, the blots were incubated with goat anti-rat IgG or goat anti-
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mouse IgG coupled to peroxidase (Jackson ImmunoResearch Laboratories, 
West Grove, PA) and developed using ECL reagents (Amersham, Arlington 
Heights, Illinois). 
Cytokine and receptor mRNA determinations: Cytokine mRNA expression 
was examined by RT-PCR. Cultured splenocytes (1 x 107 cells/ml) or day 7 
cardiac allografts were homogenized with Ultraspec (Cinna BioTex, Houston, 
TX) by repetitive pipetting and incubated for 5 minutes at 4QC. RNA was 
extracted with 0.200 ml of chloroform for each 1 ml of lysed cells. Samples 
were shaken vigorously for 15 seconds, incubated on ice for 5 minutes, and 
then centrifuged at 12,000 x g for 15 minutes at 4QC. Whole cell RNA was 
precipitated from the aqueous phase with an equal volume of isopropanol, 
incubated on ice for 15 minutes, and then centrifuged at 12,000 x g for 15 
minutes at 4QC. RNA was washed with 0.800 ml of 75% ethanol and 
centrifuged at 12,000 x g for 8 minutes at 4QC. RNA was reprecipitated with 
0.200 ml 0.2M NaCI and 0.400 ml 100% ethanol, stored at -20QC for 1 hour, 
and centrifuged at 12,000 x g for 15 minutes at 4QC. Following solubilization in 
NaCI and ethanol, the pellets were dried under vacuum for 10-15 minutes, 
dissolved in diethyl pyrocarbonate (DEPC)-treated water, and heated for 15 
minutes at 55QC. 
Total RNA concentrations were determined by optical density. Equal 
concentrations for each experimental group were confirmed by separation on a 
1 % agarose gel containing 0.5 Jlg/ml ethidium bromide. Equal concentrations of 
undiluted RNA were reverse transcribed into cDNA for the experimental 
treatment groups. Each reaction contained the following: 6 JlI 5X reverse 
transcriptase buffer (Gibco BRL, Gaithersburg, MD), 6 JlI dNTPs (10mM) 
(Perkin Elmer, Norwalk, CT), 1.0 JlI Rnasin (Promega, Madison, WI), 1.2 JlI 
19 
random primers (Promega), 3 Jll Moloney murine leukemia virus reverse 
transcriptase (M-MLV RT) (Gibco BRL), 3 Jll 1% BSA, and the appropriate 
amount of RNA (1-3 Jlg) as detennined from optical density. The final volume 
was adjusted to 30 Jll with DEPC-treated water. The reaction was incubated 
for 10 minutes at room temperature, for 60 minutes at 42QC, and then for 10 
minutes at 95QC. The cDNA was stored at -20QC until needed. 
Amplification of DNA was performed using cytokine- or receptor-specific 
primers (Clonetech, Palo Alto, CA) (Table 2-1). Each reaction contained the 
following: 5 III lOX PCR Buffer (Perkin Elmer), 22.75 Jll DEPC-treated water 
(with the exception of IL-10 which had 27.75 Jll DEPC water), 4.0 JlI eDNA, 
0.25 fll Taq polymerase (Perkin Elmer), 8 Jll dNTPs (1.25mM) (Gibco BRL), 
and 5.0 ~ of each primer (with the exception of1L-10 which had 2.5 ~ of each 
primer). Amplification occurred under the following conditions: 95QC for 1 
minute, 60QC for 2 minutes, and 72QC for 3 minutes for the indicated number of 
cycles, followed by a 7 -minute extension at 72QC. Once the number of cycles 
for each cytokine or receptor had been optimized to be on the linear portion of 
the curve, ~-actin, IL-I0, IL-12 p35, IL-12 p40, IL-15, INF-y, and TfR, were 
amplified for 30 cycles, IL-6 were amplified for 40 cycles, and IL-2, IL-2R, and 
IL-4 for 45 cycles. The DNA was stored at -20QC until needed. The amplified 
DNA was analyzed on a 1% agarose gel containing 0.5 Jlg/ml ethidium bromide 
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Quantitation of cytokine or receptor mRNA: The agarose gel was scanned 
using Snappy software (Play Inc. Rancho Cordova, CA) and quantitated using 
Gel-Pro Analyzer imaging software (Media Cybernetics, Silver Spring, MD) 
according to the manufacturer's instructions. Briefly, the scanned image was 
analyzed with single band analysis. Using the ID-Gel toolbar, the scanned 
image was rotated, lanes and bands analyzed, and data recorded as Intensity 
of Optical Density (laD). The cytokine or receptor mRNA laD was normalized 
to the ~-actin mRNA laD and recorded as the nonnalized number. 
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Transferrin receptor, a 180 kDa disulfide linked transmembrane 
glycoprotein, is a widely-distributed cell surface receptor present on most 
proliferating and differentiated quiescent cells (2, 3). TfR expression is 
increased on rapidly proliferating cells, while expression is decreased or absent 
on non-dividing cells (2). TfR binds the major serum iron transporter protein, 
transferrin, and controls iron uptake by receptor-mediated endocytosis (2, 3, 
5). TfR is not only an iron transporter, but is also involved in T cell activation 
(4, 5). However, the roles and mechanisms ofTfR in T cell activation remain 
ill-defined. 
T cell activation is a two signal process requiring antigen-specific (16, 
17) and costimulatory signals (20). The primary signal is initiated through the 
interaction of the antigen-major histocompatibility complex on APes with the 
TCR (16, 17). The secondary or costimulatory signal is provided by a co-
receptor-ligand interaction (18, 19). In some instances, this interaction is 
mediated through the CD28 co-receptor on T cells with the ligands, B7-1 and 
B7 .. 2 on APes (21-25). Only when the primary and costimulatory signals are 
received does this process lead to T cell proliferation, IL-2 production, and other 
effector functions (19, 69). Following T cell activation, IL .. 2R (16, 20) and TfR 
are up-regulated (2, 5). The expression of IL-2R is necessary for IL-2 to bind 
and assist in T cell activation (22). The increased expression ofTfR, which only 
appears after IL-2R expression, is essential for the initiation of proliferation in 
quiescent T cells (2, 12, 28). 
Monoclonal antibodies against TfR have been primarily utilized in 
cancer immunotherapy (30, 70), in which they elicit down-regulation in TfR 
expression and alterations in iron transport (71). Trowbridge et al. have 
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demonstrated that down-regulation in TfR deprives the tumor of iron, which is 
essential for continued growth and proliferation (9). In renal-cell carcinoma 
patients, absence of TfR on tumor infiltrating cells has been associated with 
poor proliferative responses (30). In contrast, peripheral T cells from these 
same patients have normal levels ofTfR and demonstrate strong proliferative 
responses (30). In a murine leukemia model, anti-TfR mAbs prolonged 
survival of tumor-bearing mice (70). However, the effects of TfR blockade on 
allogeneic immune responses are unknown. These observations suggest that 
TfR may be a potential therapeutic target in transplantation. 
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Results 
Transferrin receptor blockade prolongs cardiac allograft 
survival In order to determine the potential of TfR as a therapeutic target in 
transplantation, we utilized a murine heterotopic, nonvascularized cardiac 
allograft model. Anti-mouse TfR mAb (Dr. Jayne Lesley, Salk Institute) (72) 
was administered intravenously at 100 Jlg. The mAb utilized in these studies 
binds to the TfR epitope involved in T cell activation, which does not interfere 
with iron uptake in proliferating T cells (72). Initial studies (65) demonstrated 
that anti-TfR mAb given on the day of transplantation (day 0) and on the 
following day (day 1) significantly prolonged allograft survival to 25.7 + 0.9 
days compared to the isotype (10.7 + 0.4 days) or untreated controls (13.3 + 
0.6 days) (p<O.Ol, Wilcoxon Rank Sum) (Figure 3-1). To detennine the optimal 
dose for prolonging allograft survival, dose-response experiments were 
performed. The data revealed that anti-TfR mAb at 100 Jlg was the most 
effective dose for prolonging allograft survival (Figure 3-1) (65, 73). Anti-TfR 
mAb at 300 Jlg was no more effective than 100 Jlg on days 0 and 1 (Figure 3-1) 
(65, 73). Since TfR is found on a variety of cell types and tissues (2, 28), 
administration of high doses of anti-TfR mAb had the potential to be toxic. 
However, no significant changes in body weight or hematocrit were detected 
following high doses of anti-TfR mAb (data not shown). 
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Cardiac Allograft Survival 
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Figure 3·1. Cardiac allograft survival in mice receiving anti·TtR, mAb. 
CBAlJ (H-2k) recipients received neonatal, donor C57BL/6J (H-2b) hearts 
subcutaneously in the ear pinnae. Anti-TfR or isotype-matched control mAbs 
were administered intravenously at the indicated dose and time. The n value 
denotes the number of transplant recipients in each experimental group. 
Anti-transferrin receptor monoclonal antibody alters T cell 
effector mechanisms. CD8+ cytotoxic T lymphocytes are the primary cells 
responsible for acute allograft rejection (74). One of the current therapeutic 
strategies utilized in transplantation involves the inhibition of CTL generation 
directed against the transplanted alloantigens. Therefore, the effect of TfR 
blockade on CTL function was determined using an in vitro cell-mediated 
immunity model (66). An in vitro dose-response study revealed that anti-TfR 
mAb at 5 J,lg/ml completely abrogated the CTL response to alloantigen 
compared to the untreated and isotype controls ({i'igure 3-2) (65, 73). As 
shown in Figure 3-2, the diminished CTL responses at higher doses were not 
due to toxicity of the mAb, since the CTL responses at lower doses remained 
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partially intact (65, 73). 
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Figure 3·2. Alloantigen·specific cytotoxic T lymphocyte suppression by 
anti·TfR mAb. CBNJ (H-2k) splenocytes were stimulated in culture with 
C57BL/6 (H-2b) alloantigen for 7 days. Anti-TfR or isotype-matched control 
mAbs were administered in vitro at the indicated dose (in flg/ml) at the 
initiation of culture. Data are representative of at least three complete 
experiments. 
To determine the effect of anti-TfR mAb on proliferating T cells, a mixed 
lymphocyte response assay, which primarily assesses a CD4+ T cell response, 
was perfonned. In vitro treatment with anti-TfR mAb at 15 Jlg/ml, 5 J..lg/ml, 
and 0.5 J.!g/ml at the initiation of culture significantly (p<O.05) suppressed the 
MLR to all 0 antigen by 70-86%, 51-83%, and 4-50%, respectively, compared to 
the isotype controls (Figure 3-3). 
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Figure 3-3. In vitro administration of anti·TfR mAb suppresses T cell 
proliferation. CBNJ splenocytes were stimulated in culture with C57BU6 
alloantigen and treated with anti-TfR or isotype-matched control mAbs at the 
indicated doses (in J1,g/ml). Proliferation was determined on day 5 following 
stimulation. Data are representative of at least three complete experiments. 
* denotes p<O.05. 
Transferrin receptor blockade affects cytokine mRNA 
expression. To determine if TfR blockade altered the cytokine micro-
environment, in vitro alloantigen-stimulated cultures in the presence or 
absence of anti-TfR mAb (5 J1,g/ml) were harvested after 24 hours in culture 
and semi-quantitative RT-PCR was performed. To semi-quantitate mRNA, 
the integrated optical density (IOD) of the cytokine mRNA was normalized to 
the IOD of ~-actin mRNA. The data revealed that anti-TfR mAb suppressed 
transcription of the THI cytokines (Figure 3-4 and 3-5). Anti-TfR mAb 
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suppressed IL-2 and INF-y mRNA expression by 44% and 33%, respectively, 
compared to the isotype controls (Figure 3-4 and 3-5). IL ... 15 mRNA was not 
detected using this method. With regard to the TH2 cytokines, anti-TfR mAb 
suppressed IL-IO mRNA expression by 34% compared to the isotype control 
(Figure 3-4 and 3-5). However, IL-4 mRNA expression could not be detected 
(Figure 3-4). Since APes are essential for T cell activation, APe cytokines 
were also examined. Anti-TfR mAb had no effect on IL-12 p35 mRNA, but 
suppressed IL-12 p40 mRNA expression by 47% when compared to the 
isotype controls (Figure 3-4 and 3-5). 
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Figure 3-4. Anti-TfR mAb alters cytokine mRNA expression. Twenty-four hour alloantigen-stimulated cultures treated 
with anti-TfR mAb at 5 J..lg/ml were harvested and RNA isolated. RNA concentration was determined by optical density, 
was confirmed by gel electrophoresis, and RT-PCR was performed. Amplified DNA was analyzed on a 1% agarose gel 
containing 0.5 J..lg/ml ethidium bromide and photographed under UV light. Lane 1 = molecular weight markers, Lane 2 = 
untreated control, Lane 3 = isotype control, Lane 4 = Anti-TfR. CJ.j 
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Figure 3-5. Semi-quantitation of the cytokine mRNA expression. Twenty-four hour alloantigen-stimulated cultures 
treated with anti-TfR mAb at 5 f..Lg/ml were harvested and RNA isolated. RNA concentration was determined by optical 
density, was confirmed by gel electrophoresis, and RT-PCR was performed. Amplified DNA was analyzed on a 1% 
agarose gel containing 0.5 f..Lg/ml ethidium bromide and photographed under UV light. The cytokine mRNA IOD was 
normalized to the ~-actin mRNA IOD and recorded as the normalized IOD. These experiments were repeated at least three 
times with similar res ul ts. ~ 
~ 
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Anti-transferrin receptor monoclonal antibody alters receptors 
important in T cell activation. One of the mechanisms involved in T cell 
hyporesponsiveness may be alterations in the expression of receptors 
important during T cell activation. To determine if altered receptor expression 
was contributing to the suppressed T cell responses following in vitro 
treatment with anti-TfR mAb, receptor expression was examined on day 7 
post-treatment, at the time of CTL and MLR suppression. Anti-TfR mAb 
increased the population of cells expressing CD3 by 29% compared to the 
isotype control. The CD3 levels on the individual cells were also increased, as 
demonstrated by an increase in the mean channel fluorescence when 
compared to the isotype control (Figure 3-6 and Table 3-1). With respect to 
the CD28 costimulatory receptor and B7ligands, anti-TfR mAb increased the 
population of cells expressing CD28 and B7 by 82% and 41%, respectively, 
compared to the isotype control (Figure 3-6 and Table 3-1). Anti .. TfR mAb also 
increased CD28 and B7 expression on the individual cells as compared to the 
isotype control (Figure 3-6 and Table 3 .. 1). In contrast, anti-TfR mAb had no 
effect on the expression of CD2, another important costimulatory molecule 
(Figure 3-6 and Table 3-1). Anti .. TfR mAb had no effect on the activation 
marker IL-2R, but completely abrogated the population of TfR-expressing cells 
compared to the isotype control (Figure 3-6 and Table 3 .. 1). 
Anti-transferrin receptor monoclonal antibody alters CD4 and 
CDS expression. Since CD4 and CD8 are important co .. receptors involved in 
helper and cytotoxic T cell functions, respectively, it was important to 
determine if anti-TfR mAb alters their expression, thereby contributing to the 
suppressed proliferation and CTL lytic activity. Anti-TfR mAb increased the 
population of CD4 .. expressing cells by 35%, and also increased the number of 
CD4 co .. receptors on the individual cells as compared to the isotype control 
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(Figure 3-6 and Table 3-1). In contrast, anti-TfR mAb decreased the 
population of CD8-expressing cells by 54%, while increasing the number of 
CD8 co-receptors on the individual cells compared to the isotype control 
(Figure 3-6 and Table 3-1). Since the T cell functional assays exhibited 
immunosuppression, CD4 and CD8 cells were further defined by two-color flow 
cytometry to determine their activation status. Despite the increase in the 
number of CD4-expressing cells induced by anti-TfR mAb, the majority of 
these cells were single positive inactivated CD4+ T cells, as exhibited by the 
limited number of CD4+IL .. 2R+ T cells (83% CD4+ vs 17% CD4+IL-2R+) 
(Figure 3-7). The remaining CD8+ cells were also inactivated, since CD8+IL .. 
2R+ cells were not detected (Figure 3-7). 
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Figure 3-6. Anti-TfR mAb alters cell surface receptor expression. Flow cytometry was performed on CBAlJ splenocytes 
cultured for 7 days with C57BU6 aUoantigen in the presence of anti-TfR mAb at 5 Jlg/ml. Values represent total percent 
positive staining of activated lymphocytes for each of the cell surface markers CD3, CD4, CD8, CD2, CD28, B7, IL-2R, and 
TfR. Regular line = background, dotted line = isotype control, and bold line = anti-TfR mAb. Data are representative of 
three complete experiments. 
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Table 3. Cell Surface Expression of T Cell Markers 
In Vitro Treatment ReceptorlLigand 
%Positive (Mean channel fluorescence) 
CD3 CD4 CD8 CD2 CD28 B7 IL-2R TfR 
Isotype control 51.2 (4.5) 38.9 (7.5) 39.9 (8.9) 75.5 (2.1) 7.7 (2.5) 30.2 (9.9) 12.0 (2.0) 29.2 (8.2) 
Anti-TfR 72.2 (9.3) 60.0 (13.8) 18.4 (12.7) 85.4 (2.4) 42.0 (3.6) 51.5 (21.0) 19.7 (2.9) o (2.9) 
Flow cytometry on day 7 after treatment with anti-TfR or isotype control mAbs. Values represent total percent positive staining above 
background for each of the cell surface markers. Numbers in parentheses are mean channel flourescence for each group. Data are 
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Figure 3-7. CJ)t and CDS expressing cells remain inactive following in 
vitro treatment with anti-TfR mAh. Flow cytometry was performed on 
CBAlJ splenocytes cultured for 7 days with C57BU6 alloantigen in the 
presence of anti-TfR mAb at 5 J.lg/ml. Numbers represent total percent 
positive staining of activated lymphocytes for each of the cell surface 
markers CD4, CD8, and IL-2R. Background has been substracted. 

Figure 3-8. Indirect immunofluorescent staining of the cell surface 
transferrin receptor and protein tyrosine kinase ZAP70. EL-4 cells were 
stained with anti-TfR mAb followed by FITC-conjugated goat anti-rat IgG. 
Subsequently, cells were fixed, permeabilized, and stained with anti-ZAP70 
polyclonal antibody followed by rhodamine-conjugated donkey anti-rabbit IgG. 
(A) TfR (B) ZAP70. 
Figure a-9. Co-localization of Tm with ZAP70. EL-4 cells were stained 
with anti-TfR mAb followed by FITC-conjugated goat anti-rat IgG. 
Subsequently, cells were transferred to· 372C for 9 minutes. Cells were then 
fixed, permeabilized, and stained with anti-ZAP70 polyclonal antibody followed 
by rhodamine-conjugated donkey anti-rabbit IgG. (A) TfR (B) ZAP70 (C) TfR 
and ZAP70 (D) EL-4 cells were stained with anti-TfR mAb followed by FITC-
conjugated goat anti-rat IgG. Subsequently, cells were transferred to 37QC for 9 
minutes. Cells were then fIXed, permeabilized, and stained with rhodamine-








Anti-transferrin receptor monoclonal antibody fails to disrupt 
the association between transferrin receptor and CDS zeta-chain or 
ZAP 70. One of the mechanisms involved in altered T cell responses to 
alloantigen may be modifications in the signaling required for T cell activation. 
In addition to co-localization studies, co-immunoprecipitation experiments were 
used to demonstrate protein:protein associations. It was important to first 
demonstrate that TfR could be immunoprecipitated with mouse anti-rat TfR 
mAb in the treatment groups under the lysis conditions used. As shown in 
Figure 3-10, TfR was immunoprecipitated in all treatment groups. Since only 
the proteins associated with TfR should be detected after immunoblotting, 
protein detection was performed for CD3 zeta-chain and ZAP70. The TfR 
immunoprecipitation with EL-4 cells, using anti-TfR mAb followed by blotting 
with anti-CD3 zeta-chain or anti-ZAP70 mAbs, showed CD3 zeta-chain to be 
associated with TfR and confirmed the co-localization findings that ZAP70 was 
associated with TfR (Figure 3-10). To determine whether anti-TfR mAb 
disrupted this association, unstimulated or stimulated EL-4 cells incubated in 
the presence or absence of anti-TfR mAb, were lysed, immunoprecipitated with 
mouse anti-rat TfR mAb, and blotted with either anti-CD3 zeta-chain or anti-
ZAP70 mAbs. As shown in Figure 3-10, anti-TfR mAb failed to alter the 
association of TfR with CD3 zeta-chain or ZAP70 in the unstimulated or 
stimulated EL-4 cells (Figure 3-10). Specificity of the immunoprecipitation 
was confirmed by performing mock immunoprecipitations (Figure 3-10). Since 
anti-TfR mAb failed to alter the association of TfR with CD3 zeta-chain or 
ZAP70, tyrosine phosphorylation of CD3 zeta-chain and ZAP70 were examined 
following treatment with anti-TfR mAb. Preliminary studies suggested that 
anti-TfR mAb altered tyrosine phosphorylation (Figure 3-11). To determine if 
CD3 zeta-chain or ZAP70 were proteins affected by anti-TfR mAb treatment, 
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the immunoblot was stripped, cut, and reprobed for CD3 zeta-chain or ZAP70. 
As shown in Figure 3-11, anti-TfR mAb increased CD3 zeta-chain tyrosine 
phosphorylation in unstimulated and stimulated EL-4 cells. However, anti-TfR 
mAb appeared to decrease tyrosine phosphorylation of ZAP70 (Figure 3-11). 
In addition, these initial studies revealed that anti-TfR mAb decreased tyrosine 
phosphorylation ofpaxillin (-68 kDa), a protein involved in cell adhesion (75, 
76) (Figure 3-IIA). 
NoAb IP : TfR 
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Figure 3-10. Anti-Tffi mAb fails to disrupt the physical association of Tffi with CD3 zeta-chain or ZAP70. 
EL-4 cells unstimulated or stimulated with anti-CD3 mAb for 15 minutes in the presence or absence of anti-TfR 
mAb were lysed, immunoprecipitated (IP) with mouse anti-rat TfR mAb, and immunoblotted for TfR, ZAP70, or CD3 




Anti-TfR: - - + + 
Anti-CD3: 0 15 0 15 
IP : phosphotyrosine 
- + + 









(8) IP : phosphotyrosine 
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Figure 3-11. Anti-TfR mAb alters the activation of ZAP70. (A) EL-4 cells 
unstimulated or stimulated with anti-CD3 mAb for 15 minutes in the 
presence or absence of anti-TfR mAb were lysed, immunoprecipitated (IP) 
with anti-phosphotyrosine mAb, and immunoblotted for phosphotyrosine. H 
and L denote antibody heavy and light chains, respectively. (B) The 
immunoblot was stripped, cut, and reprobed for ZAP70 and CD3S. 
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Discussion 
TfR is a widely-distributed cell surface receptor present on most rapidly 
proliferating cells and in specialized quiescent cells that have particular needs 
for high levels of iron (2, 3).. TfR functions in iron transport, cellular growth, 
and T cell activation (4, 5). Therefore, TfR may be a novel therapeutic target 
in transplantation. A murine heterotopic, nonvascularized cardiac allograft 
model was utilized to determine the therapeutic potential of TfR blockade in 
transplantation. The data from the studies presented revealed that 
administration of anti -TfR at 100 flg on the day of transplantation and on the 
following day significantly prolonged allograft survival compared to the isotype 
control. Since the mAb used does not interfere with iron transport in 
proliferating T cells (72), the effects of anti-TfR mAb on allograft survival are 
the result of alterations in immune function rather than the lack of sufficient 
iron availability. 
Administration of anti-TfR mAb in subject animals resulted in only 
partial survival of the nonvascularized allograft. Future studies are required to 
detennine the optimal dose and timing of anti-TfR mAb for long-term allograft 
survival. Several therapeutic strategies are possible to realize this goal. First, 
TfR expression follows the induction of IL-2R in a sequence that is necessary 
for the initiation of proliferation in quiescent T cells (2, 12, 28). Therefore, 
simultaneous blockade of TfR and IL-2R may lead to long-term allograft 
survival. Second, since maximal TfR expression following T cell activation 
occurs within 48-72 hours post-stimulation (28), the appropriate timing for 
administration of anti-TfR mAb may be on days 2 and 3 post-transplantation. 
Finally, long-term allograft survival with anti-TfR mAb might be attained with 
prolonged administration of the mAb rather than a two-day course. 
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One of the possible mechanisms involved in allograft prolongation may 
be the lack of an effective immune response to alloantigen. Following 
transplantation, acute rejection is mediated primarily by cell-mediated 
immune responses (74). In vitro administration of anti-TfR mAb completely 
abrogated the CTL response to alloantigen. A dose-response study 
demonstrated that the immunosuppressive effect of anti-TfR mAb was due to 
alterations in immune function, rather than toxicity of the mAh. TfR functions 
in T cell activation as well as in iron transport (2-5). Nakamura et al. 
demonstrated that iron availability had a strong effect on CD8+ cytotoxicity 
(77). The presence of transferrin significantly enhanced the generation of 
CD8+ killer activity in the presence of IL ... 2 on tumor cells and increased 
perforin production (77). Therefore, these data suggested that the abrogation 
of the CTL response involves alterations in immune function and not iron 
accessibility. Administration of anti-TfR mAb in vitro resulted in significant 
suppression of the MLR to alloantigen, suggesting that TfR blockade at the 
time of antigen presentation can strongly inhibit proliferation and clonal 
expansion of potentially allo-reactive T cells. Suppression of cytotoxic and 
proliferative T cells by anti-TfR mAb may be contributing to the allograft 
prolongation and will need to be further defined. 
Cytokine environment can also play an important role in the 
development of an effective immune response. CD4 + TH cells can be divided 
into two subsets, THI and TH2. THI cells are responsible for classical cell-
mediated immunity such as the activation of the CD8+ CTLs, while TH2 cells 
are involved in humoral immune responses and aid in immunosuppression (78, 
79). Production of the TH2 cytokines, IL-4 and IL-IO, can inhibit the 
production of the THl cytokines, IL-2 and INF .. y(78, 79). If the primary T cell 
stimulus is accompanied by exogenous IL-4, the TH cells are committed to a 
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TH2 phenotype, while if accompanied by exogenous IL ... 12, the TH cells are 
committed to a THI phenotype (80). 
Several investigators have demonstrated expression of TH2 cytokines 
within a surviving graft, suggesting that these cytokines may have down-
regulated the cell-mediated immune responses responsible for graft rejection. 
(81-83). The potency of anti-TfR mAb as an immunosuppressant may be 
influenced by the cytokine environment. Cytokine mRNA was examined by 
semi-quantitative RT-PCR following in vitro treatment with anti .. TfR mAh. 
Anti-TfR mAb suppressed expression of mRNA for the THI cytokines, IL-2 
and INF-y, and for the TH2 cytokine, IL-4. In addition, anti-TfR mAb 
suppressed expression of IL-12 p40 mRNA. These results suggest that the 
down-regulation of IL-12 p40 mRNA may prevent development of THl cells 
(80), thereby promoting graft survival and altering cell-mediated immune 
responses. The partial effect of anti-TfR mAb on cytokine mRNA levels may 
be due to other contributing factors, such as costimulation. 
Alterations in important receptors involved in T cell activation appears 
to contribute to the suppressed immune state following in vitro treatment with 
anti-TfR mAb. Since an increase in the populations of CD3, CD28, and B7 
expressing cells were observed, anti-TfR mAb appears to have activational 
properties. T cells that encounter high levels of B7 on APC, the costimulatory 
signal generated from CD28, become fully activated (84). Subsequently, this 
activation would result in high levels of CTLA4 (84). Even though CTLA4 was 
not examined, these data suggest that this activational property of anti ... TfR 
mAb could result in increased CTLA4 expression. Based on the published 
observations that CTLA4 has an inhibitory role in T cell activation (42-45) and 
a higher affinity for B7 than CD28 (39), the negative signal generated by 
CTLA4 may be contributing to the immunosuppression seen following in vitro 
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treatment with anti-TfR mAb. Despite the activational properties of anti-TfR 
mAb, abrogation ofTfR expression may inhibit a complete T cell response. 
Since TfR blockade had a strong immunosuppressive effect on 
proliferative and cytotoxic T cell responses, anti-TfR mAb may be altering 
CD4 and CDS expression. Anti-TfR mAb increased the population of CD4-
expressing cells, which may be due to the early activational properties of the 
mAb. However, at the time of suppressed proliferation, the majority of the 
CD4+ cells lacked IL-2R expression, suggesting inactivation of these cells. In 
addition, the suppression in CTL lytic activity corresponded to a decrease in 
the population of cells expressing CDS, while the remaining CD8+ T cells lacked 
IL-2R expression. Since CD4+ and CD8+ T cells are important cells involved in 
cell-mediated immune responses, the effects on CD4- and CDS-expressing cells 
by anti ... TfR mAb demonstrate the important role of TfR in the generation of 
cell-mediated immunity. 
TfR was found to be physically associated with CD3 zeta-chain and 
ZAP70, providing further evidence that TfR is involved in T cell activation in a 
manner independent of iron transport. Therefore, one of the mechanisms 
involved in T cell hyporesponsiveness may involve alterations in the functional 
roles that TfR-CD3 zeta-chain or TfR-ZAP70 associations play in T cell 
activation. These studies demonstrate that CD3 zeta-chain and ZAP70 
associate with TfR in unstimulated and stimulated immortalized T cells, 
suggesting that these associations are independent of TCR stimulation and 
may function to amplify T cell activation. Therefore, modification in these 
associations by anti-Tffi mAb may act to inhibit activation, hence 
contributing to the altered T cell responses. Co ... immunoprecipitation 
experiments revealed this not to be the case. However in preliminary studies, 
anti-TfR mAb was found to decrease ZAP70 phosphorylation, suggesting 
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inhibition of TfR-induced signals. IfTfR functions to amplify T cell activation, 
this inhibition by anti-TfR mAb could contribute to the suppressed immune 
state. 
These data confirm previous reports that TfR is important in T cell 
activation, independent of its role in iron transport. Anti-Tffi mAb prolonged 
allograft survival and suppressed in vitro cytotoxic and proliferative T cell 
responses to alloantigen. Alterations in cytokine mRNA expression and 
signaling pathways, and modification of receptors, seem to be contributing to 
the suppressed immune state. The studies presented here represent the first 
of many required that explore the role of TfR in transplantation. Future 
studies will improve our understanding of TfR in T cell activation and in 
transplantation and will provide the knowledge necessary for utilizing TfR 
blockade as a novel therapeutic strategy in transplantation. 
CllAPTER4 
DIFFERENTIAL EFFECTS OF TRANSFERRIN RECEPTOR 




Transferrin receptor functions in cellular iron uptake (1-3) and in T cell 
activation (4, 5). However, the roles and mechanisms of TfR in T cell 
activation remain ill-defined. T cell activation is a two-signal process. The 
primary signal is provided by the interaction of the TCR with the antigen-MHC 
on the APes (16, 17). The costimulatory or secondary signal is provided by a 
co-receptor-ligand interaction (18-20). Only when both signals are received 
does this process result in proliferation, IL .. 2 production, and additional effector 
functions (18). The expression of IL-2R is up-regulated following T cell 
activation(16, 20) to allow IL-2 signaling and to assist in T cell proliferation (2, 
22). Tffi expression also increases following T cell activation after IL-2R 
expression (4, 14, 28). 
It is well-established that T cells differentiate into two distinct types of 
helper cells, TH1 or TH2, with different functions and patterns of cytokine 
secretion. THI cells are responsible for cell-mediated immune responses such 
as the activation of CD8+ cytotoxic T lymphocytes (78, 79), which are one of 
the primary cells responsible for acute rejection in transplantation (74). TH2 
cells regulate humoral immune responses and are associated with a 
suppressed immune state (78). 
Previous results in the laboratory have demonstrated that in vivo 
administration of anti-TfR mAb prolongs allograft survival and suppresses in 
vitro cytotoxic and proliferative T cell responses to alloantigen (65, 73). We 
hypothesize that in vivo blockade of TfR prolongs allograft survival by altering 
the cellular mechanisms involved in graft rejection. 
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Results 
Anti-transferrin receptor mAb prolongs cardiac allograft 
survival. Previous studies in the laboratory have demonstrated that 
administration of 100 Jlg ofanti-TfR mAb on the day of transplantation (day 0) 
and on the following day (day 1) was optimal for prolonging allograft survival 
(65, 73). Since TfR is maximally expressed between 48 and 72 hours following 
T cell activation, it was important to detennine if TfR blockade at the time of 
maximal receptor expression was more effective than TfR blockade on days 0 
and 1, at the time of antigen presentation. Anti-TfR mAb when administered 
at 100 Jlg on days 2 and 3 post-transplantation failed to prolong allograft 
survival compared to the isotype controls (13.0 + 0.0 days vs 10.5 + 0.5 days 
and 10.7 + 0.4 days) (Figure 4-1). Anti-TfR mAb at 100 Jlg on days 0 and 1 
significantly prolonged allograft survival to 25.7 + 0.9 days compared to anti-
TfR mAb on days 2 and 3 (13.0 + 0.0 days) or to the isotype controls (10.5 + 
0.5 days and 10.7 + 0.4 days) (p<O.Ol, Wilcoxon Rank Sum) (Figure 4-1). 
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Figure 4-1. Cardiac allograft survival in mice receiving anti-TfR mAb. 
CBAlJ (H-2k) recipients received neonatal, donor C57BU6J (H-2b) hearts 
subcutaneously in the ear pinnae. Anti-TfR or isotype-matched control mAbs 
were administered i.v. at the indicated dose ().1g/ml) and time. The n values 
denote the number of transplant recipients in each experimental group. 
Since administration of anti-TfR mAb on days 2 and 3 failed to prolong 
allograft survival, a four-day course of anti-TfR mAb (100 Jlg) was 
administered on days 0-3. Anti-TfR mAb on days 0-3 significantly prolonged 
allograft survival to 20.3 + 1.5 days (p=0.051) compared to the isotype controls 
(15.7 + 1.2 days) (Figure 4-2). However, anti-TfR mAb on days 0-3 was no 
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Figure 4-2. Cardiac allograft survival in mice receiving anti-TfR mAb. 
CBAlJ (H-2k) recipients received neonatal, donor C57BLl6J (H-2b) hearts 
subcutaneously in the ear pinnae. Anti-TfR or isotype-matched control mAbs 
were administered Lv. at the indicated dose and time. The n values denote the 
number of transplant recipients in each experimental group. 
Anti-TfR mAb stimulates the CTL responsiveness of allograft 
recipients. To begin to address the possible mechanisms involved in allograft 
prolongation, we determined allogeneic CTL responses for allograft recipients 
on day 7. CTL responsiveness was examined 7 days post-transplantation, 
since the animals were maintaining their grafts during the initiation of acute 
rejection (85, 86). Anti-TfR mAb on days 0 and 1 significantly increased the 
CTL response to donor-specific all 0 antigen by 16.8% (p<O.05) compared to the 
isotype control (Figure 4-3A). The primary response to naive antigen following 
administration of anti-TfR mAb was determined by a third party CTL 
response. Anti-TfR mAb significantly increased the CTL response to third 
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party alloantigen by 49.3% (p<O.Ol) compared to the isotype control. (Figure 4-
3B). Naive CBAlJ splenocytes were use as a positive control for CTL 
responsiveness. As shown in Figure 4-3A and B, CTL responsiveness to donor-
specific and third party alloantigen following in vivo treatment with anti-TfR 
mAb was at the level of a naive untransplanted animal. 
Figure 4·3. Anti-Tm mAh alters alloantigen-specific cytotoxic T 
lymphocyte responses in allograft recipients. Naive CBA, or recipients 
bearing C57BL/6 allografts 7 days post-transplantation were used as a source 
of responders. Recipients received Lv. injections of 100 Jlg of anti-TfR or 
control mAbs on the day of transplantation and on the following day. Four 
animals were used in each treatment group. Data are representative of at 
least three complete experiments. (A) Stimulators were naive donor .. specific 
C57BLl6 splenocytes. (B) Stimulators were naive third party BALB/c ByJ 
splenocytes. Mter 7 days in culture, CTL responses were determined. P 
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Anti·Tm, mAb fails to alter NK cell responsiveness of allograft 
recipients. Since several researchers have demonstrated that TfR may be 
one of the proteins targeted (87-90) during NK cell recognition and lysis, NK 
cell responses were determined for allograft recipients on day 7 post-
transplantation. Anti-TfR mAb on days 0 and 1 suppressed NK cell 
cytotoxicity by 25% compared to the isotype control, however, this 
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Figure 4·4. Anti·TfR mAb fails to significantly suppress NK cell 
responsiveness in allograft recipients. Naive CBA, or recipients bearing 
C57BU6 allografts 7 days post-transplantation were used as a source of 
effectors. Recipients received Lv. injections of 100 Jlg of anti-TfR or control 
mAbs on the day of transplantation and on the following day. Four animals 
were used in each treatment group. YAC cells were used as targets. After four 
hours, NK cell lysis was determined. 
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Anti-TfR mAb suppresses T cell proliferation in allograft 
recipients. Since CD4+ TH cells proliferate extensively following alloantigen 
recognition and costimulation (48, 73), a mixed lymphocyte response assay 
was performed to determine the immunosuppressive effects of anti-TfR mAb 
on proliferating CD4+ T cells in the allografts recipients. Anti·TfR mAb 
significantly suppressed the MLR to donor-specific alloantigen by 78.7% 
(p<O.05) compared to the isotype control (Table 4-1). The specificity of the 
allogeneic immune response following administration of anti-TfR mAb was 
determined by a third party MLR. Anti-TfR mAb significantly suppressed the 
MLR to third party alloantigen by 80.8% (p>0.05) compare-d to the isotype 
control (Table 4-1). 







Donor-Specific Third Party 
14102 + 1456 
3767 + 933 
15025 + 2009 
3198 + 215* 
(cpm) 
24491 + 3217 
22866 + 1831 
19698 + 1018 
3786 + 623* 
Cardiac recipients received i.v. injections of 100 Ilg of anti-TfR or control mAbs 
on the day of transplantation and on the following day. Splenocytes from naive 
CBA or recipients bearing C57BL/6 allografts 7 days post-transplantation 
were stimulated with donor-specific C57BL/6 or third party BALB/c 
alloantigen. Proliferation was determined on day 5 following stimulation. 
Results are expressed as mean + SEM. Data are representative of at least 
three complete experiments. * p<O.05, Student's two tailed t-test. 
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Anti·TfR, mAb suppresses TtR expression in allograft recipients. 
One of the mechanisms involved in allograft prolongation may involve 
alterations in the expression of receptors important during T cell activation. 
Cell surface receptor expression was determined by flow cytometry on days 2 
and 7 post-transplantation. Day 2 was chosen for examining receptor 
expression, since this is the time of antigen presentation (16, 20), while day 7 
was chosen since the mice were maintaining their grafts during the initiation of 
acute rejection (85, 86). On day 2 post-transplantation, splenocytes from anti-
TfR mAb-treated recipients had a 47% decrease in TfR-expressing cells 
compared to the isotype control (Figure 4-5 and Table 4-2). The levels of TfR 
were also decreased as indicated by a decrease in the mean channel 
fluorescence when compared to the isotype controls (Figure 4-5 and Table 4-2). 
Anti-TfR mAb had no effect on IL-2R or CD3 expression compared to the 
isotype control (Figure 4-5 and Table 4-2). In contrast, on day 7 post-
transplantation, splenocytes from anti-TfR mAb-treated recipients had no 
alterations in CD3, TfR, or IL-2R expression compared to the isotype controls 
(Figure 4-5 and Table 4-2). 
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Figure 4-5. Anti-TfR mAb decreases cell surface TfR rereptor expression 
in allograft recipients. Flow cytometry was performed on splenocytes from 
recipients bearing C57BU6 allografts on days 2 and 7 post-transplantation. 
Recipients received intravenous injections of 100 f.1g' of anti-TfR or control 
mAbs at on the day of transplantation and on the following day. Values 
represent total percent positive staining of activated T cells for each of the 
cell surface markers CD3, TfR, and IL-2R. Regular line = background, 
dotted line = isotype control, and bold line = anti-TfR mAb. Four animals 
were used in each treatment group. 
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Table 4-2. Cell Surface Expression of T Cell Markers on Days 2 and 7 
Post-Transplantation 
























Animals were treated with either anti-TfR or isotype control mAbs. Flow 
cytometry was performed on days 2 and 7 post-transplantation. Values 
represent total percent positive staining above background for each of the 
indicated cell surface markers. Data are representative of at least three 
complete experiments. Numbers in parentheses are mean channel 
fluorescence for each group. 
Anti-TfR mAb suppresses the T cell co-receptor, CD4, and the B7 
costimulatory ligand in the allograft recipients. Since anti-TfR mAb had 
differential effects on CD8+ CTL lytic activity and CD4+ T cell proliferation on 
day 7 post-transplantation in the allograft recipients, CD4 and CD8 expression 
were examined by flow cytometry. Costimulatory receptors and ligands were 
also examined to determine if alterations in expression were contributing to the 
prolonged cardiac allograft survival and the altered T cell responses. 
Lymphocytes were gated to examine the inactivated and activated 
populations. Anti-TfR mAb had no effect on CD4- or CD8-expressing 
inactivated cells compared to the isotype control on day 7 post-transplantation 
(Figure 4-6 and Table 4-3). Additionally, anti-TfR mAb had no effect on the T 
cell costimulatory receptors, CD28 and CD2 compared to the isotype control 
(Figure 4-6 and Table 4-3). In contrast, anti-TfR mAb decreased the number 
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of B7 expressing inactivated cells by 30% compared to the isotype control 
(Figure 4 .. 6 and Table 4 .. 3). 
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Figure 4-6. Anti-TfR mAb decreases cell surface B7 expression in allograft recipients. Flow cytometry was 
performed on splenocytes from recipients bearing C57BU6 allografts on day 7 post-transplantation. Recipients 
received i.v. injections of 100 J.lg of anti-TfR or control mAbs on the day of transplantation and on the following 
day. Values represent total percent positive staining of inactivated lymphocytes for each of the cell surface 
markers CD4, CD8, CD2, CD28, and B7. Regular line = background, dotted line = isotype control, and bold line = 
anti-TfR mAb. Two animals were used in each treatment group. 
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Table 4-3. Cell Surface Expression of T Cell Markers on 
Inactivated Lymphocytes 
In Vivo Treatment ReceptorlLigand 
% Positive (Mean channel fluorescence) 
CD4 CD8 CD2 CD28 
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B7 
Isotype control 25.6 (15.8) 2.4 (10.4) 41.0 (0.88) 7.5 (1.25) 29.5 (2.65) 
Anti-TtR 25.4 (15.9) 2.6 (9.66) 32.1 (0.83) 6.1 (1.23) 20.6 (2.47) 
Animals were treated with either anti-TfR or isotype control mAbs. Flow 
cytometry was performed on day 7 post-transplantation. Values represent 
total percent positive staining above background for each of the cell surface 
markers on the gated inactivated lymphocytes. Data are representative of at 
least three complete experiments. Numbers in parentheses are mean channel 
fluorescence for each group. 
In the activated population, anti-TfR mAb decreased CD4-expressing cells by 
28%, but had no effect on CD8 expression compared to the isotype control 
(Figure 4-7 and Table 4-4). The mAb also had no effect on the expression of the 
T cell costimulatory receptors, CD28 or CD2, or the B7 costimulatory ligands, 
as compared to the isotype control (Figure 4-7 and Table 4-4). 





Figure 4-7. Anti-TfR mAb decreases cell surface CD4 expression in allograft recipients. Flow cytometry was 
performed on splenocytes from recipients bearing C57BU6 allografts on day 7 post-transplantation. Recipients 
received i.v. injections of 100 ~g of anti-TfR or control mAbs on the day of transplantation and on the following 
day. Values represent total percent positive staining of activated lymphocytes for each of the cell surface markers 
CD4, CD8, CD2, CD28, and B7. Regular line = background, dotted line = isotype control, and bold line = anti-TfR 
mAb. Two animals were used in each treatment group. 
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Table 4·4. Cell Surface Expression of T Cell Markers on 
Activated Lymphocytes 
In Vivo Treatment ReceptorlLigand 
% Positive (Mean channel fluorescence) 





16.8 (16.5) 37.7 (11.3) 68.0 (1.35) 18.3 (1.92) 44.5 (6.15) 
12.2 (15.4) 38.3 (10.8) 62.6 (1.27) 20.3 (1.95) 44.8 (5.18) 
Animals were treated with either anti-TfR or isotype control mAbs. Flow 
cytometry was performed on day 7 post-transplantation. Values represent 
total percent positive staining above background for each of the cell surface 
markers on the gated activated lymphocytes. Data are representative of at 
least three complete experiments. Numbers in parentheses are mean channel 
fluorescence for each group. 
Anti-TfR mAb alters intragraft cytokine mRNA expression. The 
cytokine micro-environment can play an important role in the development of 
an effective immune response. Therefore, intragraft cytokine mRNA 
expression on days 2 and 7 post-transplantation was examined by semi ... 
quantitative RT-PCR. As mentioned above, days 2 and day 7 were chosen as 
appropriate times for examining intragraft cytokine mRNA expression, since 
day 2 is the time of antigen presentation (16, 20), and day 7 is the time when 
the mice were maintaining their grafts during the initiation of acute rejection. 
To semi-quantitate the mRNA, IOD of the cytokine mRNA was normalized to 
the IOD of the ~-actin mRNA. On day 2 post-transplantation, RNA from anti-
Tffi mAb-treated recipient hearts were not detected because the cells were not 
cycling (data not shown). As shown in Figures 4-8 and 4-9, anti-TfR mAb 
suppressed expression of the mRNA for the Thl cytokine, IL-15, by 70% 
compared to the isotype control, while having no effect on INF-ymRNA. There 
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was no detectable expression of IL-2 mRNA within the allografts (Figures 4-8 
and 4-9). In contrast, anti-TfR mAb increased the Th2 cytokine IL-4 mRNA 
by 93.0% compared to the isotype control (Figures 4-8 and 4-9). Anti-TfR mAb 
had an immunosuppressive effect on IL-10, however, the suppression was less 
than 50% wh n compared to the isotype control (Figures 4-8 and 4-9). Anti-
TfR mAb had no effect on expression of mRNAs for the APC cytokines IL-6, 
IL-12 p35, an IL-12 p40 (Figures 4-8 and 4-9). 
T helper 1 T helper 2 APC 
MN Ie a11R WI Ie a11R WI Ie aTfR 
IL-2 IL-4 IL-6 
IL-15 IL-10 IL-12p35 
INF-y ~-actin IL-12p40 
Figure 4·8. Anti·'ffR mAb alters intragraft cytokine mRNA expression. 
Cardiac recipients received i.v. injections of 100 J,lg of anti-TfR or control mAbs 
on the day of transplantation and on the following day. Allografts from anti-
TfR or isotype-matched control mAb-treated mice were harvested on day 7 
post-transplantation; RNA was isolated. Equal concentrations of RNA were 
determined by optical density and confirmed by gel electrophoresis. RT-PCR 
was performed. Amplified DNA was analyzed on a 1% agarose gel containing 
0.5 mg/ml ethidium bromide and photographed under a UV light. 
MW=molecular weight markers, IC=isotype-matched control mAb, aTfR=anti-
TfR mAb. Three cardiac allografts were used in each treatment group. 
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Transferrin receptor and IL·2 receptor mRNA are not expressed 
within cardiac allografts. Since TfR and IL-2R expression play pivotal roles 
in T cell activation, and since expression ofTfR follows the expression of IL-2R, 
semi-quantitative RT-PCR was performed to determine the effects of anti-TfR 
mAb on intragraft TfR and IL-2R mRNA levels on day 7 post-transplantation. 
No expression ofTfR or IL-2R mRNA was detected within the allografts (data 
not shown). 
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Figure 4-9. Seroi-quantitation of the cytokine mRNA expression. Cardiac recipients received Lv. injections of 100 J..Lg of 
anti-TfR or control mAbs on the day of transplantation and on the following day. Allografts from anti-TfR or isotype-
matched mAb-treated mice were harvested on day 7 post-transplantation; RNA was isolated. RT-PCR was performed. 
Amplified DNA was analysed on a 1% agarose gel containing 0.5 J.lg/ml ethidium bromide and photographed under UV 




Since expression of TfR on the surface has been associated with T cell 
responsiveness (30),. TfR may represent a novel therapeutic target in 
transplantation. As shown in Chapter 3, previous work in our laboratory has 
demonstrated that anti ... TfR mAb administered at 100 Jlg on days 0 and 1 of 
transplantation was the optimal dose for allograft prolongation (65, 73). 
However, maximal expression of TfR following T cell activation occurs between 
48 and 72 hours after stimulation (28), therefore, the appropriate timing for 
the administration of anti-TfR mAb was predicted to be on days 2 arId 3 post-
transplantation. However, anti-TfR mAh administered on days 0 and 1 was 
more effective. Since administration on days 2 and 3 post-transplantation was 
not effective, while moderate allograft survival was achieved on days 0 and 1, it 
was important to determine if allograft survival could be extended by a 
prolonged course of anti-TfR mAh. However, a four-day course of anti-TfR 
mAh, delivered during the time of antigen presentation and maximal TfR 
expression was no more effective than a two-day course of the mAb. The mAb 
utilized in these studies hinds to the TfR epitope involved in T cell activation, 
and does not interfere with iron uptake in proliferating T cells (72). Therefore, 
the prolonged allograft survival was the result of alterations in immune 
function rather than insufficient iron availability. During T cell activation, the 
expression of TfR follows the appearance of IL-2R. Since anti ... TfR mAb 
resulted in partial allograft prolongation with no suppression of CTLs, 
simultaneous blockade of TfR and IL-2R at the time of antigen presentation 
may be a more effective immunosuppressive regimen. Future studies will 
assess the potency of this combination in transplantation. 
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It has been suggested that TfR plays a dual roles in iron absorption and 
T cell activation. Several observations from these studies confirm this dual 
role. First, TfR blockade at the initiation of an immune response leads to 
allograft prolongation. Second, TfR blockade at the time of maximal receptor 
blockade fails to affect allograft prolongation. Lastly, the mAb used in these 
studies does not interfere with transferrin-iron binding. These observations 
suggest that TfR plays an early role in T cell activation independent of iron, 
while the later induction of TfR involves iron absorption required for cell 
proliferation. 
CD8+ CTLs are one of the primary cell types responsible for acute 
allograft rejection following transplantation. As shown in Chapter 3, previou.s 
work in the laboratory have revealed that in vitro blockade of TfR completely 
abrogated the CTL response to alloantigen (65,73), indirectly suggesting that 
CTL suppression is involved in allograft prolongation. In contrast, anti-TfR 
mAb failed to suppress the CTL response to donor-specific or third party 
alloantigen in the allograft recipients. CTLs from the allograft recipients are 
still capable of responding to alloantigen in vitro~ indicating that a state of 
unresponsiveness or anergy was not achieved. These data suggest that 
abrogation of the CTL response is not the central mechanism involved in 
allograft prolongation, and that TfR does not play a primary role in CTL 
function. However, this increased CTL activity may be responsible for the 
lack of long-term allograft prolongation. The CTL suppression to alloantigen 
observed in the transplant recipients (with or without mAb treatment), 
compared to naive CBAlJ responders, suggests a suppressed state following 
prior antigen sensitization during transplantation. Several researchers have 
demonstrated that TfR may be the structure targeted (87-90) during NK cell 
recognition and lysis. Lopez Guerrero et ale showed that several anti-TfR 
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mAbs inhibit NK cell lysis on a variety of target cells (90). Mouse L cells 
transfected with the human TfR gene became sensitive to NK cell recognition 
and lysis (91). These observations suggest that suppression of NK cell lysis, 
rather than CTL suppression, may contribute to the allograft prolongation 
seen with anti-TfR mAb. The lack of TfR mRNA expression within the 
allografts on day 7 and the lack of significant suppression of NK cell 
responsiveness confirm that NK cell activity mediated by TfR does not 
contribute to the allograft prolongation. 
Since anti-TfR mAb failed to suppress the CTL response to alloantigen, 
additional allogeneic immune responses may contribute to allograft 
prolongation, such as alterations in CD4 + proliferating T cells. The MLR, 
which is primarily a CD4+ T cell response, revealed that anti-TfR mAb-treated 
allograft recipients exhibited significant suppression to donor-specific and third 
party alloantigen. These data support our previous in vitro studies 
demonstrating that anti-TfR mAb suppresses proliferation of T cells in 
response to alloantigen, suggesting a pivotal role for TfR in T cell proliferation 
(73). Anti-TfR mAb seems to function in a global rather than in a donor-
specific manner on the proliferating T cells, since suppression of the third party 
MLR by anti-TfR mAb was as effective as the donor-specific 
immunosuppression. 
Anti-TfR mAb suppressed CD4+ T cell proliferation, while CD8+ CTL 
function remained intact. This result suggests that the mAb may alter CD4 
and CD8 expression, leading to these differential effects. During the 
examination ofCD4 and CD8 expression, we noted that anti-TfR mAb caused 
a decrease. in CD4 expression, while CD8 expression was unaffected. These 
data confirm that TfR has an important role in T cell proliferation and an 
insignificant role in CTL function. 
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T cell activation is a process that results in a step-wise progression 
through the cell cycle. The primary signal initiated through the TCR promotes 
the T cell to progress from the GO to the G1 phase of the cell cycle, while the 
costimulatory signal sends the T cell from the Gl to the S phase of the cell 
cycle. IL-2 and IL-2R form an autocrine loop following the expression of the IL-
2R, allowing for T cell progression from the G1 to the S phase (12). Several 
researchers have demonstrated that blockade of the TfR with mAbs inhibits T 
cells from entering the S phase, hence interrupting DNA synthesis and 
abrogating T cell proliferation (12, 28). Since anti-TfR mAb suppressed the 
proliferative T cells in the allograft recipients, one possible mechanism may be 
that anti-TfR mAb prevents potentially allo-reactive T cell from entering the S 
phase. Future studies will be conducted to explore the possible cell cycle 
interruption following administration of anti-TfR mAb. 
Since the cytokine micro-environment can influence the development of 
an effective immune response, intragraft cytokine mRNA expression was 
examined in cardiac allograft recipients receiving anti-TfR mAb 7 days post-
transplantation. Day 7 was chosen as the appropriate time for examining 
intragraft cytokine mRNA expression, because the animals were maintaining 
their grafts during the initiation of acute rejection (85, 86). In addition, several 
researchers have suggested that TH2 cytokines are associated with graft 
survival. CTLA4Ig in a rat renal allograft model inhibited THI and increased 
TH2 cytokine expression (81). Murine cardiac allografts considered tolerant 
expressed lower levels of IL-2 and INF-y mRNA and higher levels of IL-4 and 
IL-IO mRNA as compared to nontolerant allografts (82). In the studies here, 
anti-TfR mAb caused a decrease in the THI cytokine IL-15 mRNA, while the 
TH2 cytokine IL-4 mRNA was increased. IL-2 mRNA was undetectable in all 
the treatment groups. Since the stimulatory cytokine IL-15 mRNA was 
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expressed on day 7 post-transplantation, IL-15 appears to be a late acting 
cytokine. This result differed from IL-2 expression, which normally occurs 
within the first 24 hours after activation, thereby suggesting the window of 
detection had been missed. IL-15 has been shown to exhibit T cell stimulatory 
attributes similar to IL-2, including proliferation of primary T cells and 
induction of CTLs and lymphokine-activated killer cells (92, 93). In addition, 
IL-15 transcripts have been detected at higher levels in rejecting renal 
allografts than in nonrejecting renal allografts (94). Since the inhibitory 
cytokine IL-13 has many of the same characteristics as IL-4, the increase in 
IL-4 mRNA expression suggests that IL-13 mRNA may also be increased (95-
97), thereby contributing to the decrease in IL-15 mRNA expression. Despite 
the increase in intragraft IL-4 mRNA expression and the decrease in IL-15 
mRNA expression, allograft prolongation was moderate. This may be 
correlated with the high level ofINF-y mRNA, which suggests an effective cell-
mediated immune response. The presence of exogenous IL-12 during the 
primary T cell stimulus leads to a predominant THI phenotype. This can 
explain why expression of intragraft IL-12 p35 and p40 mRNAs were not 
altered by anti-TfR mAb, and may account for the presence of INF-y mRNA. 
There was a lack of IL-2R and TfR mRNA expression within the graft on day 7 
post-transplantation. IL-2R and TfR expression are maximal at 24-48 hours 
and 48··72 hours, respectively, following T cell activation. Therefore, the lack of 
IL-2R and TfR mRNA may indicate that the window of detection had been 
missed, rather than an absence ofT cells. In addition, the expression ofT cell-
derived cytokines would suggest the presence of T cells within the graft. 
Histological sections of the grafts could be performed to confirm the presence 
ofT cells on day 7 post-transplantation. 
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T cell activation not only requires stimulation through the TCR, but also 
requires costimulatory signals. Inhibition of these events has been shown to 
lead to altered T cell responsiveness. Anti-TfR mAb had no effect on the T cell 
costimulatory receptors, CD2 and CD28. However, the mAb used here 
suppressed the expression of B7 costimulatory ligands in the inactivated 
population. It has been suggested that limited B7 availability results 
competitive blockade of CD28 binding by CTLA4Ig resulting in inhibitory 
signals that can prevent T cell activation by interfering with the signals 
generated by CD28 and TCR (84). This appears to be the case, as evidenced 
by the reduction of CD4 + T cells in the allograft recipients following treatment 
with anti-Tffi mAb. These results suggest that anti-TfR mAb may be acting 
on the APC, thereby indirectly affecting T cell activation and proliferation. 
However, the unaltered expression of B7 in the activated population suggests 
that anti-TfR mAb fails to completely abrogate costimulation, thus resulting in 
intact CTL function and short-term allograft prolongation. The results in 
receptor and ligand expression in vivo contrasted with the receptor and ligand 
expression following in vitro treatment with anti-TfR mAh. The difference may 
be due to the examination of splenocytes rather than the graft-infiltrating cells 
and will need to be further defined. 
Kudoh et al. demonstrated that the lack of TfR on tumor infiltrating 
lymphocytes is associated with a poor immune response in renal carcinoma 
patients, while peripheral blood lymphocytes from the same patients 
expressing TfR have a strong immune response (30). In the experimental 
model, cell surface TfR expression was decreased by anti-TfR mAb at the time 
of antigen presentation, while the cell surface activation marker, IL-2R, was 
increased. As with the renal cell carcinoma patients, this reduction in TfR 
expression may be associated with the poor proliferative response 
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demonstrated in the MLR upon in vitro restimulation. However, by day 7 post-
transplantation, splenocytes from anti-TfR mAb-treated allograft recipients 
restored levels of cell surface TfR expression, hence contributing to the lack of 
long-term allograft survival by anti-TfR mAb. 
Several researchers have shown that the THI cytokines, IL-2 and INF-
'Y, strongly enhance TfR expression (98, 99). Despite the presence of INF-y 
mRNA expression within the allografts, TfR mRNA expression was not 
detected and there were no alterations in cell surface TfR expression. The up-
regulation of IL-2R during T cell activation is necessary for IL-2 to bind and 
assist in T cell proliferation. Since IL-2 mRNA expression could not be 
detected within the grafts, the lack of IL-2R expression was not surprising. 
These studies are the first to explore the T cell responsiveness of 
allograft recipients following anti-TfR mAb administration. These data confirm 
previous reports that TfR is important in T cell activation, independent of its 
role in iron transport. TfR blockade at the time of antigen presentation was 
more effective than at the time of maximal receptor expression, suggesting an 
early role for TfR in T cell responses. Anti-TfR mAb decreased TfR expression 
and suppressed T cell proliferation at the time of antigen presentation. 
Moreover, anti-TfR mAb suppressed the T cell co-receptor, CD4 and the B7 
costimulatory ligands at the time of initial acute rejection. TfR blockade down-
regulated IL-15 mRNA expression, while simultaneously up-regulating IL-4 
mRNA expression. Therefore, anti-TfR mAb may prolong allograft survival by 
shifting the TH cytokine profile, altering TfR expression, and suppressing APe 
costimulation. Even though IL-4 mRNA was strongly enhanced following anti-
Tffi mAb treatment, the presence of INF-ymRNA suggests that cell-mediated 
immune responses were still ongoing, resulting in the lack of long-term allograft 
survival. Future studies will improve our understanding of TfR in T cell 
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activation and transplantation and will provide the knowledge necessary for 
utilizing TfR blockade as a novel therapeutic strategy in transplantation. 
CHAPTER 5 
ENHANCED ALLOGRAFT SURVIVAL VIA SIMULTANEOUS 
BLOCKADE OF TRANSFERRIN RECEPTOR AND IL·2 RECEPTOR 
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Introduction 
During T cell activation, TfR expression follows the expression of IL-2R 
in a sequence that is necessary to initiate cell proliferation in quiescent T 
lymphocytes (2, 5). No interaction between IL-2R and Tffi has been 
established. However, IL-2R blockade with mAbs appears to prevent both 
TfR expression and cellular proliferation, while treatment of cells with anti-TfR 
mAb blocks only DNA synthesis without affecting IL-2R expression (2). These 
findings support the idea that growth-promoting effects assigned to certain 
lymphokines may be mediated, in part, through expression of the TfR (2). In 
addition, an undiscovered physical association between TfR and IL-2R may 
exist. 
Antibodies against TfR result in a redistribution of surface receptors 
and, in some cases, inhibit cell growth (71, 72). Since transferrin receptor 
continuously cycles between the cell surface and intracellular compartments, 
growing cells expressing TfR are extremely vulnerable to antibodies that may 
interfere with receptor function (71). Previous work with mAbs against TfR 
has been primarily in the area of cancer immunotherapy (30, 70). Recently, 
the laboratory demonstrated that anti-TfR mAb is a potent 
immunosuppressant in prolonging murine cardiac allograft survival and 
altering cell mediated immune responses (65). These studies suggest that TfR 
is a potential therapeutic target for clinical transplantation. 
The induction of IL-2R during the activation of allo-reactive T cells is a 
critical step in immune responsiveness to alloantigen. The a-chain is induced 
only after T cell stimulation, and is absent on normal resting and precursor 
cells. These features make IL-2R an ideal target for transplantation (100).The 
use of anti-IL-2Ra mAbs has prolonged allograft survival in humans (101-
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106), as well as in experimental models (107, 108), by reducing activated T 
lymphocytes and macrophages (107). In episodes of acute cellular rejection, 
blocking the IL-2/IL-2R interaction apparently inhibits ongoing cytotoxicity or 
production of cytotoxins which have been attributed to the significant decrease 
in soluble IL-2R (101), providing the opportunity for selective 
immunosuppression. 
Previous studies have demonstrated that interrupting either the TfR 
(65, 73) or IL-2R (101, 107, 108) alone prolongs allograft survival and 
suppresses cell mediated immune responses to alloantigen, but does not induce 
long term allograft survival. When assessing T cell functional capacity in the 
elderly, delayed cutaneous hypersensitivity or T cell polyclonal responses have 
been demonstrated to be significantly suppressed (109). As a result of a 
decreased IL-2 release with aging, there is a significant reduction ofTfR+ and 
IL-2R+ cell frequencies occurring during stimulation of aged T cells (109). 
Therefore, simultaneous blockade of TfR and IL-2R at the time of antigen 
presentation may reduce the T cell proliferative capacity and prolong allograft 
survival more effectively than either blockade alone. Hence, we tested the 
hypothesis that simultaneous blockade of TfR and IL-2R is more effective in 
prolonging allograft survival and suppressing T cell responses to alloantigen 
than single receptor blockade. We further hypothesized that this effect occurs 
via modification of T cell effectors to all 0 antigen. 
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Results 
Anti-Tffi and/or anti-IL-2R mAbs prolong cardiac allograft 
survival. Previous results have demonstrated that administration of anti-TfR 
(65,73) or anti-IL-2R (101, 107, 108) mAbs alone prolongs allograft survival. 
Since TfR expression follows induction of IL-2R in a sequence that is necessary 
for initiating cell proliferation in quiescent T lymphocytes (2, 5), we tested 
whether simultaneous administration of anti .. TfR and anti-IL-2R mAbs is a 
more effective in allograft prolongation. Anti-IL-2R mAb, when administered 
at 300 Jlg (14.8 + 0.9 days) or 100 Jlg (12.5 + 0.9 days) on days 0 and 1 of 
transplantation, failed to prolong cardiac allograft survival compared to the 
isotype control (15.7 + 1.2 days) (Figure 5-1A). However, extended 
administration of anti-IL-2R at 100 Jlg on days 0-5 significantly prolonged 
cardiac allograft survival (47.0 + 3.8 days) compared to the isotype control or 
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Figure 5·1. Anti·IL·2R mAb prolongs cardiac allograft survival CBAlJ 
(H-2k) recipients received neonatal, donor C57BL/6 (H-2b ) hearts 
subcutaneously in the ear pinnae. (A) Anti-IL-2R or isotype-matched control 
mAb was administered i.v. at the indicated doses on days 0 and 1 of 
transplantation. (B) Anti-IL-2R mAb was administered i.v. at the indicated 
dose and time. The n values denote the number of mice per treatment group. P 
values refer to comparison with the isotype control. 
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Anti·TtR, and/or anti·n,·2R mAbs increase CTL responsiveness to 
donor· specific and third party allogeneic CTL responses. To elucidate 
the mechanisms involved in allograft prolongation with anti-TfR and/or anti-IL-
2R mAbs, the alloantigen-specific CTL responses were determined for allograft 
recipients on day 7 post-transplantation (85, 86). Anti-TfR and/or anti-IL-2R 
mAbs significantly increased the donor-specific allogeneic CTL responses 
compared to the isotype control (p<O.05 and p<O.Ol, respectively) (Figure 5-
3A). The combination was no more effective than either agent alone. 
Similarly, anti-TfR and/or anti-IL-2R mAbs significantly increased the CTL 
response to third party alloantigen compared to the isotype control (p<O.05 
and p<O.Ol, respectively) (Figure 5-3B). Allograft recipients exhibited 
significantly suppressed CTL responses to third party BALB/c ByJ 
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Figure 5·3. Anti·TfR and/or anti·IL·2R mAbs enhance alloantigen· 
specific CTL responses. Naive CBA, or recipients bearing C57BL/6 
allografts 7 days post-transplant, were used as a source of responders. (A) 
Stimulators were naive donor-specific C57BU6 splenocytes. (B) Stimulators 
were naive third party BALB/c ByJ (H-2d) splenocytes. After 7 days in 
culture, CTL responses were determined. P values refer to comparison with 
the isotype-matched controls. 
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To determine if proliferative responses were suppressed in vivo following 
administration of anti-TfR and/or anti-IL-2R mAbs in allograft recipients on 
day 7 post-transplantation, the MLR was assessed. As discussed previously, 
this response is primarily mediated by CD4+ T cells. Anti-TfR and anti-IL-2R 
mAbs when administered alone or in combination failed to significantly 
suppress the donor-specific MLR to alloantigen as compared to the isotype 
control (data not shown). Anti-TfR mAb alone significantly (p<O.Ol) 
suppressed the MLR to third party alloantigen when compared to the isotype 
control, anti-IL-2R mAb, or the combination of anti-TfR mAb plus anti-IL-2R 
mAb. Allograft recipients showed increased MLR to donor-specific C57BU6 or 
third party BALB/c ByJ stimulators as compared to naive CBAlJ splenic 
lymphocytes (data not shown). 
Anti·TfR, and/or anti·IL·2R mAbs fail to significantly suppress 
NK cell cytotoxicity. Several investigators have reported that TfR is one of 
the cell surface receptors targeted during NK cell recognition and lysis (87-90). 
Therefore to determine if the immunosuppressive effects of anti-TfR and/or 
anti-IL-2R mAbs were the result of NK cell suppression, NK cell cytotoxicity 
was assessed in the allograft recipients 7 days post-transplantation. Anti-TfR 
mAb suppressed NK cell cytotoxicity compared to the isotype control, anti-IL-





NK Cytotxicity of 
Allograft Recipients 
___ Naive CBA 





Effector: Target Ratio 
87 
Figure 5·4. Anti-Tm and/or anti·IL·2R mAbs fail to significantly 
suppress NK cell cytotoxicity. Naive CBA, or recipients bearing C57BL/6 
allografts 7 days post-transplant, were used as a source of effectors. YAC 
were used as a source of targets. After a 4 hour Cr-51 release assay, NK cell 
lysis was determined. P refer to comparison with the isotype controls. 
Anti·TfR, and/or anti·IL·2R mAbs exhibit differential effects on T 
cell activation receptors. Since anti-TfR (65, 73) and/or anti-IL-2R mAbs 
prolong allograft survival, we used flow cytometry to examine the expression of 
various cell surface receptors important in T cell activation on days 2 and 7 
post-transplantation. On day 2, at the time of antigen presentation, anti-TfR 
or anti-IL-2R mAbs alone failed to suppress the expression of the T cell 
marker, CD3, while the combination of anti-TfR and anti-IL-2R mAbs 
increased the number of CD3-expressing cells by 24% compared to the isotype 
control (Figure 5-5A). Alterations were not detected in the mean channel 
fluorescence with any of the treatment groups (Figure 5-5A). Anti-Tffi mAb 
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alone and in combination with anti-IL-2R mAb suppressed the number ofTfR-
expressing cell by 47% and 27%, respectively, and decreased the number of 
TfR on the individual cells compared to the isotype control as demonstrated by 
the mean channel fluorescence (Figure 5-5A). However, anti-IL-2R mAb alone 
failed to suppress TfR expression (Figure 5-5A). Anti .. TfR and/or anti-IL-2R 
mAbs failed suppress IL ... 2R expression, but anti-TfR mAb alone increased the 
number of IL-2R on the individual cells compared to the isotype control (Figure 
5-5A). By day 7, anti-IL-2R mAb alone and in combination with anti-TfR mAb 
decreased the number of CD3-expressing cells on day 7 by 46% and 55%, 
respectively, while CD3 expression on the individual cells was similar to that of 
the isotype control (Figure 5-5B). Anti-TfR mAb failed to suppress TfR 
expression, while anti-IL-2R mAb alone or in combination with anti-TfR mAb 
increased the number of TfR-expressing cells by 75% and 82%, respectively, 
and increased TfR expression on the individual cells (Figure 5-5B). No 
intragraft TfR mRNA expression was detected by RT-PCR on day 7 post-
transplantation (data not shown). Anti-TfR mAb alone failed to suppress the 
number of IL-2R-expressing cells compared to the isotype control on day 7 
(Figure 5-5B). However, anti-IL-2R mAb alone suppressed IL-2R-expressing 
cells by 66%, while the combination decreased IL-2R expression by 42%, 
compared to the isotype control (Figure 5 .. 5B). Anti-TfR and/or anti ... IL ... 2R 
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Figure 5-5. Anti-Tffi and/or anti-IL-2R mAbs alter T cell activation 
markers. Flow cytometry of splenocytes from naive CBAlJ, or recipients 
bearing C57BU6 allografts. (A) Day 2 allograft recipients. (B) Day 7 allograft 
recipients. Values represent total percent positive staining of activated T cells 
for each of the cell surface markers CD3, TfR, and IL-2R. Numbers in 
parentheses denote the mean channel fluorescence. 
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Anti·TfR and/or anti·IL·2R mAbs have differential effects on 
cytokine mRNA expression. To determine if the intragraft cytokine micro-
environment was altered by the administration of anti-TfR and/or anti-IL-2R 
mAbs, semi-quantitative RT-PCR was performed on cardiac allografts on days 
2 and 7 post-transplantation (85, 86). RNA was not detected on day 2, since 
the T cells had not been initiated for migration through the cell cycle. On day 7,. 
anti-Tffi mAb failed to suppress intragraft mRNA expression for the THI 
cytokines, IL-2 and INF-y. However, anti-TfR mAb suppressed the THI 
cytokine IL .. 15 by 69% compared to the isotype control (Figures 5-6 and 5-7). 
In contrast, anti-IL-2R mAb alone increased IL*2 and INF-yby 78% and 30%, 
respectively, while suppressing IL .. 15 by 50% compared to the isotype 
controls. Simultaneous administration of anti-TfR and anti-IL-2R mAbs 
decreased IL-15 and INF-y by 50% and 35%,. respectively, while completely 
abrogating IL ... 2 mRNA expression (Figures 5-6 and 5-7). Anti-TfR mAb and/or 
anti-IL-2R mAb increased IL-4 mRNA expression by 93-96% compared to the 
isotype control. Anti-TfR mAb decreased IL-IO mRNA expression by 45%. 
Anti-IL-2R mAb alone had slight enhancing effects on IL-IO mRNA expression 
(12%), while the combination had no effect compared to the isotype control 
(Figures 5-6 and 5-7). Anti-TfR mAb alone had slight immunosuppressive 
effects on IL-6 (10%), IL-12 p35 (29%), and IL-12 p40 (16%) mRNA 
expression compared to the isotype controls. Anti-IL-2R mAb alone increased 
IL-6 and IL-12 p35 mRNA expression by 22% and 29%,. respectively, 
compared to the isotype controls, while anti-IL-2R mAb suppressed IL-12 p40 
mRNA expression by 41%. Simultaneous administration of anti-TfR and anti-
IL-2R mAbs exhibited a slight decrease in IL-6 (13%) and a slight increase in 
IL-12 p35 (11%) mRNA expression, while completely abrogating IL-12 p40 
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Figure 5-6. Anti-TfR and/or anti-IL-2R mAbs alter intragraft cytoldne mRNA expression. Cardiac allografts 
from anti-TfR and/or anti-IL-2R or isotype-matched control mAb-treated mice were harvested on day 7 post-
transplantation; RNA was isolated. Equal concentrations of RNA were determined by optical density and 
confirmed by gel electrophoresis. RT-PCR was performed, and amplified DNA was seperated on a 1% agarose 
gel containing 0.5 Jlg/ml ethidium bromide and photographed under UV light. Lane 1 = molecular weight 
markers, Lane 2 = isotype control, Lane 3 = anti-TfR, Lane 4 = anti-IL-2R, and Lane 5 = anti-TfR + anti-IL-2R. 
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Figure 5-7. Semi-quantitationofcytokine mRNAexpression. Cardiac allografts from anti-TfR and/or anti-IL-
2R or isotype-matched control mAb-treated mice were harvested on day 7 post-transplantation; RNA was isolated. 
Equal concentrations of RNA were determined by optical density and confirmed by gel electrophoresis. RT-PCR 
was performed, and amplified DNA was seperated on a 1% agarose gel containing 0.5 J.lg/ml ethidium bromide 
and photographed under UV light. Cytokine mRNA laD was normalized to p-actin mRNA laD and recorded as 
the normalized laD. to 
l.\:) 
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Simultaneous administration of anti·TtR and anti-IL-2R mAbs in 
vitro suppresses primary T cell responsiveness to alloantigen. The 
effects of simultaneous administration of anti-TfR and anti-IL-2R mAbs in 
vitro on T cell responsiveness to alloantigen were examined further by 
investigating the direct effects of these agents on the generation of the primary 
alloantigen-specific CTL responses and MLR. As previously shown (65), the 
addition of anti-TfR mAb at 5 ~g/ml to alloantigen-stimulated cultures 
completely abrogated the alloantigen-specific CTL response (p<O.Ol) (Figure 5-
8A). The addition of anti-IL-2R mAb at the initiation of culture significantly 
suppressed the CTL response as compared to the isotype control (p<O.Ol) 
(Figure 5-SA). The combination of anti-TfR plus anti-IL-2R mAb, while 
completely abrogating the CTL response when compared to anti-IL-2R mAb or 
the isotype control, was no more immunosuppressive than anti ... TfR mAb alone 
(p<O.Ol) (Figure 5-8A). Anti-TiN and/or anti-IL-2R mAbs failed to suppress 
CTL responsiveness to alloantigen when administered at the time of lytic 
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Figure 5-8. Simultaneous administration of anti-TfR mAb and anti-IL-
2R mAbs in vitro completely abrogates CTL responsiveness to 
alloantigen. CBAlJ splenocytes were stimulated in culture with C57BL/6 
alloantigen for 7 days. (A) Anti-TfR and/or anti-IL-2R or isotype control mAbs 
were administered in vitro at the initiation of culture at 5 Jlg/ml. (B) Anti-TfR 
and/or anti-IL-2R or isotype control mAbs were administered at 5 Jlg/ml at the 
time of lytic assay. Data are representative of at least three complete 
experiments. P values refer to comparison with the isotype-matched controls. 
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The in vitro effects of anti-TfR and anti-IL-2R mAbs on proliferative 
responses to alloantigen were also evaluated. Consistent with previously-
reported results, anti-TfR mAb significantly suppressed the primary MLR as 
compared to the isotype control (p<O.05) (Table 5-1). However, anti-IL-2R 
mAb failed to suppress the MLR as compared to the isotype control or anti-
TfR mAb (Table 5-1). Simultaneous administration of anti-TfR and anti-IL-2R 
mAb significantly suppressed the MLR as compared to the isotype control, 
however, it was no more immunosuppressive than anti-TfR mAb alone 
(p<O.01) (Table 5-1). 






Anti-TfR + Anti-IL-2R 
Day 3 
11193 + 1057 
4718 + 333* 
6883 + 210 
3350 + 297* 
Day 5 
15352 ± 1079 
3218 + 512* 
19309 + 974 
1163 + 69** 
CBAlJ (H-2k) responder splenocytes were stimulated with C57BLl6 (H-2b) 
alloantigen and treated with anti-TfR and/or anti-IL-2R or isotype-matched 
control mAbs at 5 Jlg/ml during the initiation of culture. Proliferation was 
determined on day 3 and 5 following stimulation. Data are representative of at 
least three complete experiments. (* denotes p< 0.05; ** denotes p<O.01) 
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Discussion 
As previously mentioned in Chapter 3, observations have established 
that allograft prolongation was found when anti-TfR mAb was administered at 
the time of transplantation in the murine, cardiac allograft model (65, 73). 
Others have demonstrated allograft prolongation in humans (101-106) and 
experimental animal models (107, 108) following administration of anti-IL-2R 
mAb. Both regimens not only prolonged allograft survival, but suppressed cell 
mediated immune responses. Nevertheless, long term allograft survival was 
not demonstrated by either agent alone. TfR expression follows the induction 
of IL-2R during T cell activation in a sequence that is necessary for initiating 
cell proliferation in quiescent T lymphocytes (2, 5). Therefore, we tested the 
hypothesis that simultaneous blockade of TfR and IL-2R is more effective in 
prolonging allograft survival and suppressing T cell responses to alloantigen 
than single receptor blockade. We further hypothesized that this effect occurs 
by modifying the response ofT cell effectors to alloantigen. 
Anti-TfR and anti-IL-2R mAbs are effective immunosuppressive agents 
in prolonging allograft survival in the murine, heterotopic nonvascularized 
allograft model. As previously reported, anti-TfR mAb prolonged allograft 
survival when administered at the time of antigen presentation (65). In 
contrast, a two-day course of anti-IL-2R mAb at the time of antigen 
presentation failed to prolong allograft survival. However, an extended, six-day 
course of anti-IL-2R mAb prolonged allograft survival to a greater extent than 
anti-TfR mAb. Likewise, simultaneous administration of a two-day course of 
anti-TfR and anti-IL-2R mAbs was more immunosuppressive than either 
agent alone. These data suggest that both TfR and IL-2R play important roles 
in T cell activation during alloantigen stimulation, and that both receptors need 
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to be blocked at the time of antigen presentation, antigen-specific T cell 
priming, and cell surface receptor up-regulation in order to achieve the most 
effective regimen of immunosuppression. Previous studies have supported the 
synergistic effectiveness of combining anti-IL-2R mAb antibodies with other 
immunosuppressive agents, such as cyclosporine and steroids, to influence 
different steps in the immune cascade (102 .. 106). However, side effects from 
this non-specific immunosuppression resulted. The approach to blocking two 
receptors that are not expressed on immune cells until activation, provides a 
novel strategy for prolonging allograft survival without the systemic side 
effects seen with currently-used regimens. 
To elucidate the mechanisms responsible for the extended allograft 
prolongation following the administration of anti-TfR plus anti-IL-2R mAb, we 
examined the ability of splenic T lymphocytes from cardiac allograft recipients 
to respond to donor-specific stimulators in vitro. Anti-TfR and anti-IL-2R 
mAbs, alone or in combination, increased the CTL response to alloantigen. 
However, the combination was no more effective than either agent alone. 
Similarly, anti-TfR and/or anti-IL-2R mAbs elevated the CTL responsiveness 
to third party-alloantigen. CTLs from the allograft recipients were capable of 
responding to alloantigen in vitro, indicating that a state of anergy had not 
been achieved. The suppressed CTL response to third party alloantigen by the 
transplant recipients compared to naive CBNJ responders indicates a 
suppressed immune state following antigen sensitization. The stimulatory 
effects of anti-TfR and/or anti-IL-2R mAbs suggests a negative regulatory role 
for TfR and IL-2R on day 7 during the time of an ongoing immune response and 
the initiation of acute rejection. Administration of anti-TfR and/or anti-IL-2R 
mAbs may be blocking the interaction of these ligands with unknown negative 
regulators, thereby providing stimulatory signals. Previous studies utilizing 
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anti-IL-2R mAb in combination with cyclosporine, which failed to prolong 
allograft survival in a rat small bowel model, exhibited constant cytotoxic and 
suppressor T lymphocytes, even in the presence of decreased IL-2R and 
reduced activated T lymphocytes (107). Likewise, cytotoxic T lymphocyte 
responses to alloantigen were not completely abrogated in our model following 
simultaneous administration of anti-TfR and/or anti-IL-2R mAbs, suggesting 
that additional activation signals such as costimulatory pathways appear to 
be important in T cell responsiveness. An analogy exists between prolonged 
allograft survival following the administration of anti-Tffi and anti-IL-2R 
mAbs and the reduction of T lymphocyte function in the elderly (109). In 
immune responses in the aged, the decrease in TfR and IL-2R expression has 
implied a reduced frequency of activation (109) that is similar to the 
hyporesponsive immune state seen in the allograft recipients following the 
administration of anti-TfR and/or anti-IL-2R mAbs. 
Since CTL responsiveness to alloantigen was not the pnmary 
mechanism responsible for the allograft prolongation following administration 
of anti-TfR and/or anti-IL-2R mAbs, NK cell recognition and lysis were 
explored. Previous reports have demonstrated TfR to be one of the structures 
targeted during NK cytotoxicity, and several anti-TfR mAbs inhibit NK cell 
lysis on a variety of target cells. (87-90) Anti-TfR and/or anti-IL-2R mAbs had 
minimal immunosuppressive effects on NK cell cytotoxicity. In addition, the 
lack ofTfR mRNA expression within the allografts on day 7 confirms that NK 
cell activity mediated by TfR was not contributing to the allograft prolongation. 
To assess alterations in T cell markers important during activation, flow 
cytometry was performed following administration of anti-TfR and/or anti-IL-
2R mAbs. Day 2 and 7 were chosen for studying T cell activation markers, 
since day 2 was during the time of antigen presentation and receptor up .. 
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regulation (16,20), while day 7 was when the mice are still maintaining their 
grafts during the initiation of acute rejection when the mice were maintaining 
their grafts (85, 86). During early antigen presentation and receptor up-
regulation (day 2), anti-TfR and/or anti-IL-2R mAbs failed to suppress cell 
surface receptor expression of the T cell marker, CD3. However, anti-TfR 
mAb suppressed the T cell activation marker, TfR. In contrast, anti-IL-2R 
mAb increased both T cell activation markers, TfR and IL-2R during antigen 
presentation. This observation may explain why allograft survival was not 
achieved. The decrease in TfR expression without an increase in IL-2R by 
anti-TfR plus anti-IL-2R mAbs at the time of antigen presentation may be 
responsible for prolonged allograft survival. However by day 7 during an 
ongoing immune response, anti-IL-2R mAb alone and in combination with anti-
TfR mAb suppressed CD3 expression. This implies that a negative T cell 
activation signal from the IL-2/IL-2R pathway may be up-regulating TfR to 
compensate or support the contribution of a decreased antigen-specific signal 
following simultaneous administration of these mAbs. In addition, the decrease 
in the number of CD3 expressing cells following anti-IL-2R mAb alone or in 
combination with anti-TfR mAb may result from complement binding or Fc:Fc 
receptor interaction generating an apoptotic signal and needs to be further 
defined. 
Blocking the signals at the time of activation, rather than during the 
time of an ongoing immune response, alters the expression TfR and appears to 
reflect the conditions contributing to prolonged graft survival. High levels of 
IL-2R+ cells have been demonstrated in the peripheral blood of untreated 
monkeys receiving renal transplants (108). Treatment of these recipients with 
anti-IL-2R mAbs diminished the expression of IL-2R for 6 days post-mAb 
treatment (108). However in our model, anti-TfR and/or anti-IL-2R mAbs had 
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only slight effects on IL-2R expression, suggesting that alterations in IL-2R 
expression were not the primary mechanism responsible for graft prolongation 
in the model. 
Since the cytokine micro-environment at the time of antigen 
presentation can potentially affect the type of effector T cells, we assessed 
intragraft cytokine expression on day 7 post-transplantation (85, 86). Recent 
reports have suggested an association between the presence of TH2 cytokines 
and graft survival (81, 82). Anti-TfR mAb suppressed the THI activation 
cytokine IL-15, while failing to suppress IL-2 and INF-ymRNA expression. IL-
15 may be functioning as a late activational cytokine after the initiation of an 
immune response, while IL-2 and INF -y may appear early during activation. 
Anti-IL-2R mAb alone increased IL-2 and INF-y while suppressing IL-15 
mRNA expression. While anti-IL-2R mAb has been reported to suppress IL-2 
and INF-y production, the responses were measured during the of time 
antigenic stimulation. Therefore, the observed immunosuppression may be 
due to the decrease in the late activation cytokine IL-15. In addition, the 
immunosuppressive effects of anti-IL-2R mAb may be less than expected 
because of the high levels of IL-2 mRNA expression, which may over-ride the 
reduced IL-15 mRNA expression. However, the combination of anti-TfR and 
anti-IL-2R mAbs decreased IL-2, INF-y, and IL-15 mRNA expression 
compared to the isotype control. Therefore, the enhanced immunosuppressive 
effect of anti-TfR plus anti-IL-2R mAbs during allograft survival may be due to 
the suppression of all three T cell activation cytokilles during the time of acute 
rejection. 
With respect to the TH2 cytokine, IL-4, anti-TfR and/or anti-IL-2R mAb 
increased IL-4 mRNA expression as compared to the isotype control. The 
combination was more effective than either agent alone, suggesting that the 
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up-regulation of IL-4 and the down-regulation of the THI cytokines by the 
combination provided the ideal micro-environment to enhance graft survival. 
The suppression of IL-10 mRNA expression by anti-TfR mAb may partially 
explain why anti-TfR mAb alone does not exhibit extended allograft survival. 
Anti-TfR and/or anti-IL-2R mAbs had only slight effects on the APe cytokines, 
IL-6 and IL-12 p35 mRNA expression, while the combination of anti-TfR and 
anti-IL-2R mAbs completely abrogated the IL-12 p40 mRNA expression, 
possibly contributing to prolonged allograft survival. Since the presence of IL-
12 commits a TH cell to a TH1 phenotype, the lack of IL-12 p40 in the 
combination of anti-TfR and anti-IL-2R mAbs may contribute to the decrease 
in the TH1 cytokines, thereby resulting in extended allograft survival. 
To understand the effects of anti-Tffi and anti-IL-2R mAbs in the 
induction of T cell suppression, in vitro assays were performed to delineate the 
abilities of these agents to inhibit primary T cell responses. Anti-TfR, as 
previously reported (73), and anti-IL-2R (108) mAbs alone suppressed the 
CTL response to alloantigen. Anti-TfR mAb was more effective than anti-IL-
2R mAb, while the combination was no more effective than anti-TfR mAb 
alone. These agents were more effective during antigen presentation than 
during the time of an ongoing immune response or effector functioning. Anti-
TfR mAb, as previously reported (73), was effective in suppressing the 
proliferative state of activated T cells as demonstrated by the in vitro MLR. 
Anti-TfR mAb alone was as effective as when combined with anti-IL-2R 
mAbs. The immunosuppression resulting from anti-TfR and/or anti-IL-2R 
mAbs in these in vitro systems demonstrates the abilities of these antibodies 
to suppress cytotoxic and proliferative responses in vitro, but amplifies the 
reality that the response to these agents in vivo are influenced by a variety of 
unknown biological factors that will need to be defined. 
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We have demonstrated that anti-TfR and anti-IL-2R mAbs have 
significant immunosuppressive properties as demonstrated by their abilities to 
prolong allograft survival in the heterotopic, nonvascularized cardiac allograft 
model. Simultaneous blockade of TfR and IL ... 2R at the time of antigen 
presentation was more effective than application of either agent alone. The 
combination of anti-Tffi and anti-IL-2R mAbs increased cytotoxic T 
lymphocyte responses to donor-specific and third party alloantigen, while 
decreasing the T cell activation markers TfR and IL-2R at the time of antigen 
presentation. These agents down-regulated mRNA for IL-2, INF-yand IL-15, 
while simultaneously up-regulating IL ... 4 mRNA. Therefore, these 
immunosuppressive agents shift the TH cytokine paradigm and alter T cell 
activation receptors. Understanding the immunosuppressive mechanisms 
involved during the novel blockade ofTfR and IL-2R in transplantation will lead 
to antigen-specific immunosuppression without affecting physiological host 
immmle systems, an important goal in clinical transplantation. 
CHAPTER 6 
MODULATION OF TRANSFERRIN RECEPTOR DURING ALTERED 
T CELL RESPONSES 
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Introduction 
T cell activation requires antigen .. specific (16, 17) and costimulatory 
signals (18 .. 20) that result in proliferation, IL-2 production, and other effector 
functions (22, 23, 110, 111). The antigen .. specific or primary signal is mediated 
by interaction of the TCRlCD3 complex on T cells with antigen presented in the 
context of MHC class I or class lIon APes (16, 17). The costimulatory or 
secondary signal is provided by a co-receptor-ligand interaction in which the 
ligand is provided by the APC (18-20). Following T cell activation, IL .. 2R and 
TfR expression are up-regulated in a sequence necessary for T cell 
proliferation. IL-2R expression is necessary for IL-2 to bind and assist in T cell 
proliferation, while the increased expression ofTfR is essential for initiating T 
cell proliferation in quiescent cells (1, 12, 18). Blockade of these events has 
been shown to alter T cell responses to alloantigen. 
The TCR is noncovalently associated with the nonpolymorphic multi .. 
chain complex, CD3, which consists of at least four protein subunits or chains 
referred to as ,,(, 0, £, and ~ homodimer (35). The ex and ~ chains of the TCR 
form the antigen-binding subunit, while the CD3 complex is responsible for 
signal transduction (32-34). The TCRlCD3 complex is involved in antigen-
specific T cell responses, such as CTL function, that eliminate cells expressing 
viral and tumor antigens. In addition, allogeneic cells are potent inducers and 
targets of CTLs (33). The secondary signal can be generated through the 
CD281B7 pathway. CD28 and CTLA4 bind to both ligands, B7 .. 1 and B7-2 (25-
27, 46, 47). However, CTLA4 binds with 20-fold higher avidity than CD28 (39). 
CD28 is found on mature peripheral T cells, activated B cells, and plasma cells 
(47). CTLA4 is expressed on the surface of activated T cells and has recently 
been found to, be a potential negative regulator of T cell activation (42-45). 
105 
Previous studies have shown that blocking the antigen-specific and 
costimulatory signals with anti-CD3 mAb or CTLA4Ig, respectively, can 
prolong allograft survival and alter cell-mediated immunity (37,38, 48, 49). 
Appearance of IL-2R following T cell activation is an important step in 
the development of an effective immune response to alloantigen. IL-2 plays a 
pivotal role in the progression of graft rejection (101, 103). The binding of IL-2 
to the receptor results in T cell proliferation, generation of effector cells, and 
the release of various cytokines (18). The use of mAbs against IL-2Ra have 
prolonged allograft survival in humans (101-106) as well as experimental 
models (107, 108) by suppressing activated T lymphocytes and their 
subsequent effector responses to the graft (103, 107). In episodes of acute 
cellular rejection, blocking the IL-2/IL-2R interaction apparently inhibits 
ongoing cytotoxicity and/or production of cytotoxins. These mechanisms have 
been attributed to the significant decrease in soluble IL-2R (101). 
Transferrin receptor, a disulfide-linked transmembrane glycoprotein, is a 
widely-distributed cell surface receptor expressed on rapidly-proliferating 
normal cells, transformed cells, and specialized quiescent cells which have high 
requirements for iron (2, 3). TfR expression is essential for continued growth 
and is closely linked to the proliferative status of a cell. TfR has been found to 
be physically associated with the CD3 zeta-chain and with the tyrosine kinase, 
ZAP70;, suggesting that TfR-induced signals are transduced through the CD3 
zeta-chain (30). 
Previous results in the laboratory have demonstrated that 
administration of anti-TfR mAb prolongs allograft survival and suppresses 
cytotoxic and proliferative T cell responses to alloantigen (65, 73). Anti-CD3 
mAb, CTLA4Ig, and anti-IL-2R mAb interrupt signals that occur prior to the 
expression of TfR during T cell activation. U sing these current 
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immunosuppressants, which are specific for each of the steps involved in T cell 
activation prior to Tffi. expression, will allow for examination of receptor 
modulation and provide possible roles for TfR in T cell activation. Modification 
of TfR expression by these immunosuppressants may contribute to the 
suppressed immune state seen following transplantation and needs to be 
further defined. The goal of these studies was to explore the modulation of TfR 
during altered T cell responses. 
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Results 
CD3 blockade suppresses cytotoxic and proliferative T cell 
responses. Prior to TfR expression, T cell activation requires interaction of 
the TCRlCD3 complex with antigen-self MHC and costimulatory signals 
generated through costimulatory pathways that include CD28/B7. Blockade of 
these interactions has been shown to lead to altered T cell responses. As 
previously demonstrated in the laboratory (37), anti-CD3 mAbs have 
immunosuppressive effects on CD8+ CTLs. Anti-CD3 mAb completely 
abrogated the CTL response to alloantigen compared to the isotype control 
HRa4 (Figure 6-1). Since T cells proliferate extensively following alloantigen 
stimulation, a MLR was performed to examine the in vitro effect of anti-CD3 
mAb on proliferating T cells. Anti-CD3 mAb completely abrogated 
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Figure 6·1. AIloantigen·specific cytotoxic T lymphocyte suppression by 
anti·CD3 mAb. CBAlJ (H-2k) splenocytes were stimulated in culture with 
C57BL/6 (H-2b) alloantigen for 5 days. Anti-CD3 mAb or isotype control 
HRa4 were administered in vitro at 5 f.lg/ml at the initiation of culture. Data 
are representative of at least three complete experiments. 
Table 6-1. Effects of Anti·CD3 mAb on Proliferating Splenocytes 





15426 + 1529 
o +0* 
CBAlJ splenocytes were stimulated in culture with C57BU6 alloantigen and 
then treated with the indicated immunosuppressant at 5 J,1g/ml. Proliferation 
was determined on day 5 following stimulation. Results are expressed as mean 
cpm + SEM. Data are representative of at least three complete experiments. 
(* denotes p<O.Ol compared to HR(4). 
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CD281B7 blockade suppresses cytotoxic and proliferative T cell 
responses. As previously demonstrated in the laboratory (48, 49), CTLA4Ig 
has immunosuppressive effects on CD8+ CTLs. CTLA4Ig significantly 
suppressed the CTL response by 58% compared to control fusion protein L6 
(p<O.05) (Figure 6-1B). An MLR was performed to demonstrate the in vitro 
effect of CTLA4Ig on proliferating T cells. As seen for the CTL response, 
CTLA4Ig was less immunosuppressive for proliferating T cells than was anti-
CD3 mAb. CTLA4Ig significantly suppressed the MLR by 57% compared to 
L6 (p<O.01) (Table 6-1). 
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Figure 6-2. AIloantigen-specific cytotoxic T lymphocyte suppression by 
CTLA4Ig. CBAlJ (H-2k) splenocytes were stimulated in culture with 
C57BL/6 (H-2b) alloantigen for 5 days. CTLA4Ig or control fusion protein L6 
were administered in vitro at 5 Jlg/ml at the initiation of culture. Data are 
representative of at least three complete experiments. 
Table 6·2. MLR of CTLA4Ig Treated Splenocytes 





42859 + 2137 
18385 ± 422* 
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CBAlJ splenocytes were stimulated in culture with C57BU6 alloantigen and 
treated with the indicated immunosuppressant at 5 Jlg/ml. Proliferation was 
determined on day 5 following stimulation. Results are expressed as mean cpm 
± SEM. Data are representative of at least three complete experiments. (* 
denotes p<O.05 compared to L6). 
CD3 blockade alters transferrin receptor expression. Since anti-
CD3 mAb blocked the antigen-specific signal leading to altered T cell responses 
to alloantigen, time course studies were performed to explore the modulation of 
TfR expression during these responses. On day 1 post-treatment, anti-CD3 
mAb increased the total population of cells expressing TfR by 43%, while 
decreasing the mean channel fluorescence. The latter change indicates a 
decrease in the number of individual TfR receptors on individual cells as 
compared to the isotype control HRa4 (Figure 6-3 and Table 6-3). CD3 and IL-
2R expression were also examined. Anti-CD3 mAb increased the total 
population of cells expressing IL-2R by 63%, as well as the number of 
individual receptors on the cells, when compared to HRa4 (Figure 6-3 and 
Table 6-3). In contrast, anti-CD3 mAb completely abrogated CD3 expression 
compared to HRa4 (Figure 6-3 and Table 6-3). By day 3 post-treatment, anti-
CD3 mAb failed to alter the percentage of cells expressing TfR as compared to 
HRa4 (Figure 6-3 and Table 6-3). Similar to day 1 post-treatment, the 
number ofTfR on individual cells was decreased on day 3 after anti-CD3 mAb 
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(Figure 6-3 and Table 6-3). Anti ... CD3 mAb increased IL ... 2R expression, ,vhile 
completely abrogating CD3 expression as compared to HRa4 on day 3 post-
treatment (Figure 6-3 and Table 6-3). On day 5 post-treatment, anti-CD3 
mAb had no effect on the. total population of TfR-expressing cells, decreased 
the number of Tffi on individual cells, increased IL-2R expression, and 
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Figure 6-3. Anti-CD3 mAb alters expression of the T cell activation 
markers. Flow cytometry was performed on days 1, 3, and 5 post-treatment 
on splenocytes treated in vitro with anti-CD3 mAb at 5 Jlg/ml. Regular line = 
background, dotted line = isotype control HRa4, and bold line = anti-CD3 
mAb. Data are representative of at least three complete experiments. 
Table 6-3. Cell Surface Expression ofT Cell Markers 
Receptor In Vitro Treatment Day Post-Treatment 
Day 1 Day 3 Day 5 
TfR HRa4 33.2 (12.7) 25.3 (16.8) 70.5 (7.1) 
Anti-CD3 58.4 (8.6) 28.1 (5.7) 69.9 (3.0) 
IL-2R HRa4 30.7 (2.4) 40.1 (3.6) 48.1 (2.6) 
Anti-CD3 86.5 (6.2) 87.6 (6.3) 89.1 (5.9) 
CD3 HRa4 49.9 (6.8) 35.4 (7.3) 74.8 (4.4) 
Anti-CD3 o (5.1) o (4.0) o (1.6) 
Flow cytometry was performed on days 1, 3, and 5 post-treatment. Values represent 
total percent positive staining above background for each of the cell surface 
markers. Data are representative of at least three complete experiments. Numbers 
in parentheses indicate the mean channel fluorescence for each group. 
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CD281B7 blockade fails to alter transferrin receptor expression. 
To determine the effect of CTLA4Ig on TfR expression during altered T cell 
responses, time course studies were performed. In contrast to anti-CD3 mAb 
on days 1, 3, and 5 post-treatment, CTLA4Ig failed to alter either the 
population of cells expressing TfR or the number of TfR expressed on individual 
cells as compared to the control fusion protein L6 (Figure 6-4 and Table 6-4). 
In addition, CTLA4Ig had no effect on IL-2R or CD3 expression as compared to 
L6 on days 1, 3, and 5 post-treatment (Figure 6-4 and Table 6-4). 
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Figure 6-4. CTLA4Ig fails to alter expression of the T cell activation 
markers. Flow cytometry was performed on days 1, 3, and 5 post-treatment 
on splenocytes treated in vitro with CTLA4Ig at 5 Jlg/ml. Regular line = 
background, dotted line = control fusion protein L6, and bold line = CTLA4Ig. 
Data are representative of at least three complete experiments. 
Table 6-4. Cell Surface Expression of T Cell Markers following 
CTI.A4Ig treatment 
Receptor In Vitro Treatment Day Post-Treatment 
Day 1 Day 3 Day 5 
TfR L6 34.1 (4.8) 16.5 (6.0) 16.2 (3.6) 
CTLA4Ig 30.8 (3.9) 21.2 (5.8) 20.1 (3.5) 
IL-2R L6 22.0 (1.8) 17.5 (4.0) 18.1 (1.7) 
CTLA4Ig 23.2 (2.1) 16.9 (3.4) 25.5 (1.9) 
CD3 L6 56.9 (24.7) 84.0 (30.3) 88.9 (27.8) 
CTLA4Ig 59.1 (26.3) 82.1 (29.1) 86.0 (25.2) 
Flow cytometry was performed on days 1, 3, and 5 post-treatment. Values represent 
total percent positive staining above background for each of the cell surface 
markers. Numbers in parentheses indicate the mean channel fluorescence for each 
group. Data are representative of at least three complete experiments. 
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Anti·Tm and/or anti·IL·2R mAb suppress cytotoxic and 
proliferative T cell responses. During T cell activation, the appearance of 
TfR follows the expression of IL-2R. The immunosuppressive effects of anti-
TfR and/or anti-IL-2R mAbs in the in vitro system were previously 
demonstrated utilizing AlIa CTL and MLR assays. Anti-TfR or anti-IL-2R 
mAbs alone significantly suppressed the CTL response to alloantigen by 88% 
and 25%, respectively, compared to the isotype control E7 (p<O.OOl) (Figure 6-
5). In addition, the combination of anti-TfR and Anti-IL-2R mAbs significantly 
suppressed the CTL response by 88% and 91%, respectively, as compared to 
E7 or anti-IL-2R mAb alone (p<O.OOl and p<O.05, respectively) (Figure 6-5). 
Anti-TfR or anti .. IL .. 2R mAbs alone significantly suppressed proliferation by 
89% and 69%, respectively, as compared to E7 (p<O.05) (Table 6-5). The 
combination of anti-IL-2R and anti-TfR mAbs significantly suppressed the 
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Figure 6·5. TtR and/or IL·2R blockade suppress cytotoxic T 
lymphocytes. CBAlJ (H-2k) splenocytes were stimulated in culture with 
C57BU6 (H-2b) alloantigen for 5 days. Anti-TfR and/or anti-IL-2R or isotype-
matched control mAbs were administered in vitro at 5 J.1g/ml at the initiation of 
culture. Data are representative of at least three complete experiments. 
Table 6-5. Mixed Lymphocyte Response 







13368 + 1396 
1505 + 173* 
4161 + 442* 
1444 ± 90* 
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CBNJ splenocytes were stimulated in culture with C57BU6 alloantigen and 
treated with the indicated immunosuppressant at 5 Jlg/ml. Proliferation was 
determined on day 5 following stimulation. Results are expressed as mean cpm 
+ SEM. Data are representative of at least three complete experiments. (* 
denotes p<O.05 compared to E7). 
Anti·Tm mAb alone or in combination with anti·IL·2R mAb 
suppresses Tm expression. Despite the fact that anti-IL-2R mAb alone 
suppressed cytotoxic and proliferative T cell responses to alloantigen, this mAb 
failed to alter TfR and CD3 expression on days 1, 3, and 5 post-treatment 
(Figure 6-6 and Table 6-6). However, anti-IL-2R mAb decreased the 
population of cells expressing IL-2R by 78-88% and decreased the number of 
IL-2R on individual cells as compared to the isotype control E7 (Figure 6-6 and 
Table 6-6). In contrast, anti-TfR mAb alone decreased the population of cells 
expressing TfR by 98-100% compared to E7 on days 1, 3, and 5 post-
treatment (Figure 6-7 and Table 6-7). In addition, anti-TfR mAb decreased the 
population of IL-2R-expressing cells by 22% and 17% on days 3 and 5 post-
treatment, respectively, but had no effect on day 1 post-treatment as 
compared to E7 (Figure 6-7 and Table 6-7). Anti-TfR mAb increased the 
population of CD3-expressing cells by 17-39% on days 1, 3, and 5 post-
treatment compared to E7 (Figure 6-7 and Table 6-7). The combination of 
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anti-TfR and anti-IL-2 mAbs was the most effective on receptor expression, 
decreasing the population of TfR expressing cells by 94-100% and IL-2R 
expressing cells by 85 .. 91% on days 1, 3, and 5 compared to E7 (Figure 6-8 and 
Table 6-8). In contrast, the combination failed to increase the population of 
CD3 ... expressing cells as compared to E7, anti-TfR mAb, or anti-IL-2R mAb 
(Figures 6-6, 6-7, and 6-8) (Table 6-6, 6-7, and 6-8). The combination increased 
CD3 expression on days 3 and 5 post-treatment compared to E7 (Figure 6-8 
and Table 6-8). 
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Figure 6-6. Anti-IL-2R mAb fails to alter expression of the T cell 
activation marker TfR. Flow cytometry was performed on days 1, 3, and 5 
post-treatment on splenocytes treated in vitro with anti-IL-2R mAb at 5 
~g/ml. Regular line = background, dotted line = isotype control E7, and bold 
line = anti-IL-2R mAb. Data are representative of at least three complete 
experiments. 
Table 6-6. Cell Surface Expression ofT Cell Markers following 
anti-IL-2R mAb treatment 
Receptor In Vitro Treatment Day Post-Treatment 
Day 1 Day 3 Day 5 
TfR E7 30.0 (10.7) 43.2 (14.5) 66.9 (6.1) 
Anti-IL-2R 35.3 (13.2) 39.2 (17.0) 66.5 (7.4) 
IL-2R E7 33.3 (2.3) 46.2 (3.3) 3B.2 (2.1) 
Anti-IL-2R 7.4 (1.1) 9.B (1.6) 4.7 (1.4) 
CD3 E7 31.1 (6.6) 20.2 (6.0) 66.B (3.5) 
Anti-IL-2R 42.B (7.7) 32.1 (B.l) 74.2 (4.3) 
Flow cytometry was performed on days 1, 3, and 5 post-treatment. Values represent 
total percent positive staining above background for each of the cell surface 
markers. Numbers in parentheses indicate the mean channel fluorescence for each 
group. Data are representative of at least three complete experiments. 
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Figure 6-7 Anti-TfR mAb alters expression of the T cell activation 
markers. Flow cytometry was performed on mAb on days 1, 3, and 5 post-
treatment on splenocytes treated in vitro with anti-TfR at 5 Jlg/ml. Regular 
line = background, dotted line = isotype control E7, and bold line = anti-Till 
mAb. Data are representative of at least three complete experiments. 
Table 6-7. Cell Surface Expression ofT Cell Markers following 
anti-TfR mAb treatment 
Receptor In Vitro Treatment Day Post-Treatment 
Day 1 Day 3 Day 5 
TfR E7 30.0 (10.7) 43.2 (14.5) 66.9 (6.1) 
Anti-TfR o (5.9) o (5.6) 1.2 (1.6) 
IL-2R E7 33.3 (2.3) 46.2 (3.3) 38.2 (2.1) 
Anti-TfR 37.6 (2.1) 35.9 (2.3) 31.8 (2.3) 
CD3 E7 31.1 (6.6) 20.2 (6.0) 66.8 (3.5) 
Anti-TfR 42.5 (7.7) 33.0 (8.2) 76.2 (4.6) 
Flow cytometry was performed on days 1, 3, and 5 post-treatment. Values represent 
total percent positive staining above background for each of the cell surface 
markers. Numbers in parentheses indicate the mean channel fluorescence for each 
group. Data are representative of at least three complete experiments. 
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Figure 6-8. Combination of anti-TfR and anti-IL-2R mAbs alters 
expression of the T cell activation markers. Flow cytometry was 
performed on days 1, 3, and 5 post-treatment on splenocytes treated in vitro 
with anti-TfR and anti-IL-2R mAbs at 5 Jlg/ml. Regular line = background, 
dotted line = isotype control E7, and bold line = anti-TfR and anti-IL-2R 
mAbs. Data are representative of at least three complete experiments. 
Table 6-8. Cell Surface Expression of T Cell Markers following 
anti-TfR and anti-IL-2R mAbs treatment 
Receptor In Vitro Treatment Day Post-Treatment 
Day 1 Day 3 Day 5 
TfR E7 30.0 (10.7) 43.2 (14.5) 66.9 (6.1) 
Anti-TfR/Anti-IL-2R o (7.0) 0 (6.1) 4.1 (1.6) 
IL-2R E7 33.3 (2.3) 46.2 (3.3) 38.2 (2.1) 
Anti-TfR/Anti-IL-2R 5.1 (1.1) 4.1 (1.4) 3.7 (1.2) 
CD3 E7 31.1 (6.6) 20.2 (6.0) 66.8 (3.5) 
Anti-TfR/Anti-IL-2R 37.2 (6.8) 34.6 (8.3) 75.1 (4.7) 
Flow cytometry was performed on days 1, 3, and 5 post-treatment. Values represent 
total percent positive staining above background for each of the cell surface 
markers. Numbers in parentheses indicate the mean channel fluoroscence for each 
group. Data are representative of at least three complete experiments. 
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Discussion 
Previous work in the laboratory has demonstrated that anti-CD3 mAb 
is an effective inducer of allograft prolongation and a suppressor of cello. 
mediated immunity (37). One of the possible mechanisms that may contribute 
to this immunosuppression is altered in TfR expression, sin'ce TfR has been 
found to be physically associated the CD3 zeta-chain~ and TCRlCD3 signaling 
occurs prior to TfR expression. These studies revealed that anti-CD3 mAb 
decreased the number of TfR on individual cells. This decrease in TfR 
corresponded to the abrogation of CD3 expression, suggesting that the 
reduction in surface TfR may be the consequence of its physical association 
with the CD3 zeta-chain. Anti-CD3 mAb treatment resulted in an early 
increase in the population of TfR-expressing cells. This response is probably 
due to the activational properties of the mAb, suggesting the induction ofTfR 
expression involves signals generated by CD3 engagement. The activational 
properties of anti-CD3 mAb are also demonstrated by the persistent increase 
in IL-2R expression following antibody treatment. These studies were the first 
to demonstrate a down-regulation in TfR expression following CD3 blockade. 
Our data suggest that this response may contribute to the immuosuppression 
induced by anti-CD3 mAb. 
Blockade of the costimulatory signal induced by the CD28/B7 
interaction generates hyporesponsiveness in T cells by various mechanisms 
(48-50). CTLA4Ig had no effect on TfR, CD3, or IL-2R expression as 
demonstrated by flow cyto me try. Signaling through the CD28 costimulatory 
receptor results in p70 86 kinase activation, inducing T cells to progress from 
G1 to the 8 phase of the cell cycle (112-117). TfR expression is necessary for 
cells to progress through 8 phase (12,28). However, the results suggest that 
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TfR expression is not influenced by the signals generated through CD28 
engagement. Miskimins et al. demonstrated that fibroblasts treated with 
rapamycin, a known 86 kinase inhibitor, failed to affect TfR promoter activity 
(118). These results are consistent with the data presented here. 
The expression of IL-2R is up-regulated following T cell activation and is 
necessary for IL-2 to bind to its receptor and thereby assist in T cell 
proliferation (18). IL-2 and IL-2R form an autocrine loop, with the expression 
of IL-2R allowing the T cell to progress from the Gl to the S phase of the cell 
cycle (18). Previous studies with IL-2R-blocking mAbs showed abrogation of 
both IL-2R and TfR expression, with cells remaining in the GO to Gl phase of 
the cell cycle (1, 28). However, our studies demonstrated that anti-IL-2R mAb 
down .. modulated IL-2R expression, while TfR expression remained intact. 
These data suggest that alterations in TfR expression do not contribute to the 
immunosuppression, and that the signals generated prior to TfR expression by 
IL-2R engagement are not involved in TfR induction. These results are not 
surprising in light of the fact that CD28, which is also involved in T cell 
progression from Gl to S phase, failed to alter TfR expression. 
Previous work in the laboratory has demonstrated that anti .. TfR mAb 
decreased TfR expression on day 7 post-treatment (unpublished observation). 
These studies also showed that anti ... TfR mAb alone or in combination with 
anti-IL-2R mAb decreased TfR expression. Previous studies with other mAbs 
including anti-CD2 and anti-CD3 mAbs, demonstrated that the major 
mechanism involved in CD2 and CD3 down-modulation is internalization of 
receptor .. antibody complexes. Therefore, TfR modulation by anti-TfR mAb 
may be the result of internalization. Anti-TfR mAb alone or in combination 
with anti-IL-2R mAb decreased IL-2R and increased CD3 expression. Despite 
the recruitment ofCD3-expressing cells, the lack ofTfR and/or IL-2R appears 
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to contribute to the suppressed T cell responses. 
The goal of these studies was to explore the modulation of TfR during 
altered T cell responses, which may provide insight into the possible roles of 
TfR during T cell activation. These studies demonstrated that the induction of 
TfR expression is independent of CD28 and IL-2R signaling, while CD3 
signaling is involved in the promotion of TfR expression. These studies 
suggests that TfR has an early role in T cell activation. Furthermore, we have 
delineated an additional mechanism involved in anti-CD3 mAb 
immunosuppression by showing that TCRlCD3 blockade results in TfR down-
modulation. Thus, the hyporesponsiveness observed following the 
administration of these immunosuppressants results from several 
mechanisms. These studies further define possible roles of TfR in T cell 
activation. 
CllAPTER7 
ROLE OF TRANSFERRIN RECEPTOR IN T LYMPHOCYTE 




Administration of DST prior to transplantation results in allograft 
prolongation in humans and in animal models (53 .. 57). Wood et ale 
demonstrated using a chronic cardiac allograft rejection model, that rats 
receiving a single DST 14 days prior to transplantation were able to overcome 
chronic rejection episodes (57). Such episodes are a common barrier in long .. 
term allograft survival. DST have also been shown to act synergistically with 
current immunosuppressive therapies (58,59, 119). Anderson et ale reported 
that kidney transplant patients receiving DST in combination with 
azathioprine failed to be sensitized to donor antigens, such that transplanted 
grafts were successful without rejection or loss (56). 
The mechanisms responsible for allograft prolongation following DST are 
largely unknown. Clinically, the immunosuppressive effects of blood 
transfusions have been shown to be associated with decreases in the number 
and function of lymphocytes. van Twuyver et ale revealed that DST with one 
HLA haplotype .. match led to cytotoxic T lymphocyte (CTL) unresponsiveness 
in patients awaiting renal transplant (60). It has also been suggested that 
DST leads to shifts in the T helper lIT helper 2 paradigm (55, 62, 63) and 
induces a selective decrease in the use of certain TCR V~ families (120, 121), 
Both effects may contribute to allograft prolongation. Delineation of the 
mechanism(s) responsible for the immunosuppressive effects of DST may 
provide better immunosuppressive regimens for clinical transplantation. 
As mentioned previously, TfR has a dual role in iron transport and T cell 
activation, and TfR expression is partially controlled by the intracellular iron 
content. Therefore, we hypothesize that alterations in T cell responsiveness to 
alloantigen following DST may be associated with changes in TfR expression. 
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To begin addressing this hypothesis, time course experiments were performed 




Donor-specific blood transfusion suppresses the cytotoxic T 
lymphocyte response to alloantigen. Several researchers have 
demonstrated allograft prolongation following administration of DST at various 
time points prior to transplantation. Therefore, we performed time course 
studies to assess T cell responsiveness and expression of cell surface receptors 
important in T cell activation following DST. Pilot experiments performed on 
days 1, 3, 5, 7 and 10 post-transfusion demonstrated that T cell 
responsiveness and receptor expression were most affected on days 3 and 5 
post-transfusion. Therefore, we focused the experiments on this time period. 
Since one of the hallmarks of allograft rejection is T cell activation and 
the recruitment of CTLs, proliferative and cytotoxic T cell functions were 
examined. CBNJ recipients received i.v. injections of 0.200 ml of freshly-
isolated whole heparinized autologous (CBAlJ) or donor C57BL/6 blood. 
Heparin has been shown to effect lymphocyte function. Eskinazi et ale 
demonstrated that heparin-treated cultures have a two- to four-fold higher 
production of IL-2 in the culture supernatants and exhibit increased numbers 
of T cells as compared to non-heparinized cultures (122). To control for the 
presence of heparin in the transfused mice, control mice received 0.200 ml of 
heparinized saline. As shown in Figure 7-1, DST significantly suppressed the 
CTL response to alloantigen on day 3 post-transfusion by 60% compared to 
the saline control (p<O.Ol). To assess whether the immunosuppressive effect 
was due to the presence of alloantigen and blood components or to the blood 
components alone, the CTL response was examined following the transfusion 
of autologous blood. On day 3 post-transfusion, autologous blood failed to 
suppress the CTL response to alloantigen compared to the saline control 
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(Figure 7-1). Consequently, DST significantly suppressed the CTL response by 
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Figure 7-1. Donor-specific blood transfusions suppress alloantigen-
specific cytotoxic T lymphocyte responses on day 3 post-transfusion. 
CBNJ (H-2k) recipients received i.v. injections of 0.200 ml of whole heparinized 
C57BL/6 (H-2b) or autologous CBNJ blood. Control animals received i.v. 
injections of 0.200 ml of heparinized saline. Three animals were used in each 
treatment group. Transfused CBAlJ splenocytes on day 3 post-transfusion 
were used as a source of responders. Responder splenocytes were stimulated 
in culture with C57BU6 (H-2b) alloantigen for 7 days. After 7 days in culture, 
CTL responses were determined. P values refer to comparison with the saline 
and autologous controls. 
Since CD4+ T helper cells proliferate extensively following recognition of 
alloantigen and costimulation, the effects of DST on proliferating T cells were 
examined. As shown in Table 7-1, DST failed to alter the MLR to alloantigen 
as compared to the saline or autologous controls. 
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Table 7·1. Mixed Lymphocyte Response 
Day Post-Transfusion 
Transfusion Treatment Day 3 Day 4 Day 5 
Saline 25196 + 2370 21743 + 1490 16299 + 877 
Autologous 17648 + 1133 24562 + 745 9702 + 552* 
DST 22069 + 1804 31873 + 1775* 26627 + 4474 
Splenocytes from transfused CBAlJ mice were stimulated in culture with 
C57BL/6 alloantigen. Proliferation was determined on day 5 following 
stimulation. Results are expressed as mean cpm + SEM. (* p<0.05, compared 
to saline control). 
Blood transfusions decrease transferrin receptor expression on 
day 3 post-transfusion. Since TfR is involved in iron absorption and T cell 
activation, DST with its accompanying iron load mediated by the 
tranferrin:iron complexes may be altering the expression and regulation of TfR 
resulting in the immunosuppression. Flow cytometry was utilized to detennine 
whether alterations in cell surface expression ofTfR occurred following DST. 
On day 3 post-transfusion, TfR expression was decreased on splenocytes from 
DST- and autologous-treated recipients by 74% and 89%, respectively, 
compared to the saline control (Figure 7-2 and Table 7-2). A shift in the mean 
channel fluorescence also demonstrated a decrease in the number of TfR on 
individual cells (data not shown). To determine if blood transfusions were 
altering other cell surface receptors important in T cell activation, IL .. 2R and 
CD3 expression were also examined. On day 3 post-transfusion, IL-2R 
expression was reduced in DST- and autologous-treated recipients by 92% and 
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88%, respectively, compared to the saline control (Figure 7-2 and Table 7-2). 
Donor-specific- and autologous-blood also increased CD3 expression by 49% 
and 51%, respectively, compared to the saline control (Figure 7-2 and Table 7-
2). To demonstrate the CD3-expressing population in the CD3 histograms, 
saline control splenocytes were incubated with unconjugated 145-2Cll 
hamster anti-mouse CD3 mAb followed by FITC 145-2Cll hamster anti-
mouse CD3 mAh. As shown in Figure 7-3, blockade of eD3 prior to FITC 
labeling resulted in the disappearance of the bright population, verifying this 
peak as the CD3-specific population. The dim population was confirmed to be 
a nonspecific peak by using Fe block prior to eD3 staining (data not shown). 
DST and autologous blood had no effect on the mean channel fluorescence 
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Figure 7-2. mood transfusions alter T cell activation markers. Flow cytometry was performed on splenocytes 
from transfused recipients on days 3-5 post-transfusion. Regular line = background, dotted line = saline control, 




Table 7-2. Cell Surface Expression of T Cell Markers following 
Blood Transfusions 
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Receptor Transfusion Treatment Day Post-Transfusion 
Day 3 Day 4 Day 5 
Saline 33.5 19.5 27.6 
TtR Autologous 3.6 19.4 21.9 
DST 8.7 25.3 20.7 
Saline 2.6 13.4 17.5 
IL-2R Autologous 21.7 11.3 17.7 
DST 30.8 19.5 25.4 
Saline 28.7 51.0 37.8 
CD3 Autologous 58.1 50.1 41.6 
DST 55.9 44.3 43.1 
Flow cytometry was performed on splenocytes from transfused recipients on days 3-5 
post-transfusion. Values represent total percent positive staining above background for 







Figure 7-3. Verification of the CIX3 population. Flow cytometry was 
performed on splenocytes from heparinized saline-transfused recipients on 
day 3 post-transfusion. Regular line = background, dotted line = 145-2C11 
hamster anti-mouse CD3 mAb followed by FITC 145-2Cll hamster anti-
mouse CD3 mAb, and bold line = FITC 145-2Cll hamster anti-mouse CD3 
mAb. 
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Recovery of alloantigen-specific T cell responsiveness following 
donor-specific blood transfusions. The early suppression of the CTL 
response appeared to be dependent on the presence of alloantigen and blood 
components. However, continued exposure to alloantigen following DST 
resulted in a loss of the immunosuppressive influence of the blood components. 
In contrast to day 3 post-transfusion, DST significantly increased the CTL 
response to alloantigen on days 4 and 5 post-transfusion by 30% and 28%, 
respectively, compared to the saline controls (p<0.05) (Figures 7-4A and B). 
On days 4 and 5 post-transfusion, autologous blood failed to alter the CTL 
responses to alloantigen compared to the saline controls (Figures 7 -4A and B). 
DST had similar effects on proliferating T cells. DST significantly increased the 
MLR on day 4 post-transfusion by 32% compared to the saline controls 
(p<O.05) (Table 7-1). On day 5 post-transfusion, DST increased the MLR by 
39%, however, this change was not statistically significant (Table 7-1). On day 
5 post-transfusion, autologous blood significantly suppressed the MLR by 40% 
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Figure 7-4. Donor-specific blood transfusions increase alloantigen-
specific cytotoxic T lymphocyte responses on days 4 and 5 post-
transfusion. CBNJ (H-2k) recipients received i.v. injections of 0.200 ml of 
whole heparinized C57BU6 (H-2b) or autologous CBAlJ blood. Control animals 
received i.v. injections of 0.200 ml of heparinized saline. Three animals were 
used in each treatment group. (A) Transfused CBNJ splenocytes on day 4 
post-transfusion were used as a source of responders. (B) Transfused CBAlJ 
splenocytes on day 5 post-transfusion were used as a source of responders. 
Responder splenocytes were stimulated in culture with C57BL/6 alloantigen 
for 7 days# After 7 days in culture, CTL responses were determined. P values 
refer to comparison with the saline and autologous controls. 
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Donor-specific blood transfusion alters cell surface receptor 
expression. In contrast to the CTL responses, suppression of early cell 
surface TfR expression on day 3 post-transfusion appeared to be influenced 
solely by blood components. At the time of CTL recovery on days 4 and 5 post ... 
transfusion, TfR expression was at the level of control animals. DST and 
autologous blood had no major effect on TtR or CD3 expression compared to 
the saline controls on days 4 and 5 post-transfusion (Figure 7-2 and Table 7 ... 2). 
In contrast, DST had subtle effects on IL-2R with increases of 31 % on both 
days, while autologous blood had no effect compared to the saline controls 
(Figure 7-2 and Table 7-2). 
Blood transfusions influence the TfR,+IL-2R+ lymphocyte 
population. TfR expression follows the appearance of IL-2R in a step-wise 
manner that is essential for T cell activation. In order to examine the effect of 
blood transfusions on this process, two-color flow cytometry was utilized. On 
day 3 post-transfusion, DST and autologous blood recipients have few TfR+ or 
IL-2R+ lymphocytes compared to the saline control (Figure 7-5). However, 
DST and autologous blood resulted in increases in TfR+IL-2R+ (DP) 
lymphocytes of 65% and 53%, respectively, compared to the saline control 
(Figure 7-5). On days 4 and 5 post-transfusion, at the time of CTL recovery, 
DST increased the DP lymphocytes by 21% and 23%, respectively, while 
autologous blood had no effect compared to the saline controls (Figure 7-5). On 
day 5 post-transfusion, DST increased single positive TfR+ lymphocytes 
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Figure 7-5. Donor-specific blood transfusions alter 1he double positive 
TfR+IL-2R+ lymphocytes. CBAlJ (H-2k) recipients received an i.v. 
injections of 0.200 ml of whole heparinized C57BU6 (H-2b ) or autologous 
CBAlJ blood. Control animals received an i. v. injection of 0.200 ml of 
heparinized saline. Three animals were used in each treatment group. 
Splenocytes from transfused CBAlJ were used for flow cytometry. Values 
represent total percent single- and dual-positive staining for TfR and IL-
2R above background. 
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Discussion 
DST has been shown to have beneficial effects on allograft prolongation 
(53-57). However, the mechanisms responsible for allograft prolongation with 
DST are primarily unknown. Cytotoxic T lymphocyte unresponsiveness, 
production of TH2 cytokines while hindering THI cytokine production, and 
selective decreases in the expression of certain TCR V~ families are some of 
the mechanisms that have been implicated in improved allograft survival 
following DST (55, 62, 63, 120, 121). This study was the first to examine the 
immunosuppressive effects of donor-specific blood transfusions in association 
with alterations in TfR function and regulation. Previous results in the 
laboratory have demonstrated using a murine heterotopic, nonvascuralized 
cardiac allograft model that in vivo administration of anti-TfR mAb prolonged 
allograft survival, and that in vitro treatment with anti-TfR mAb suppressed 
cytotoxic and proliferative T cell responses (65, 73). Since the antibody used in 
these studies does not interfere ,\lith transferrin binding, the effects of anti-TfR 
mAb on T cell function are the result of alterations in immune function rather 
than the lack of iron availability. In addition, co-immunoprecipitation 
experiments using Jurkat, a human T cell line, demonstrated that TfR was 
physically associated with the CD3 zeta-chain and the protein tyrosine kinase, 
ZAP70 (29). Experiments performed in the laboratory using EL ... 4, a murine T 
cell line, showed that TfR can associate with CD3 zeta-chain and ZAP70 in a 
murine T cell line (Chapter 3). These results when taken together suggest a 
strong role for TfR in T cell activation and imply that Tffi functions 
independently from its iron absorption role to affect T cell activation. 
Therefore, DST, with their accompanying iron loads, may alter the function 
and regulation ofTfR in T cell activation and allograft rejection. 
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Since T cell activation and the recruitment of CTL effectors are 
fundamental in the pathogenesis of allograft rejection (74), the effects of DST 
on cytotoxic and proliferative T responses to all 0 antigen were determined. Time 
course experiments demonstrated that DST suppressed the CTL response to 
alloantigen on day 3 post-transfusion, suggesting that DSTs have an early 
immunosuppressive effect despite the presence of alloantigen. Since DST was 
immunosuppressive in the model, it was important to determine whether the 
blood components alone were responsible for this immunosuppression. 
Therefore, transfusion of autologous blood was also examined under these 
conditions. On day 3 post-transfusion, autologous blood failed to alter the CTL 
response, suggesting that the immunosuppressive effect was contingent on the 
presence of alloantigen in combination with additional blood components. In an 
orthotopic hepatic rat model, DST resulted in allograft prolongation while third 
party blood failed to prolong allograft survival, suggesting that the beneficial 
effects of DST require antigen-specific priming (123). These results support 
the data showing that DST requires the presence of alloantigen priming in 
order to be effective. In contrast to the effects on CTL on day 3 post-
transfusion, DST failed to alter the MLR to alloantigen. These results suggest 
that DST may be more effective on CTLs than on proliferating T cells in the 
presence of alloantigen. 
The suppression of the CTLs was transient, since DST increased the 
CTL response to alloantigen on days 4 and 5 post-transfusion. In order to 
exert a continued immunosuppressive effect, DST may need to be 
administered in combination with current immunosuppressive agents such as 
azathioprine or cyclosporin A. Since autologous blood failed to alter the CTLs 
on days 4 and 5 post-transfusion, the increased CTL caused by DST may have 
resulted from alloantigen priming. A similar stimulatory effect was evident in 
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the MLR following DST on days 4 and 5 post-transfusion. This recovery in the 
CTL suggests that the continued presence of alloantigen following DST 
overcomes the beneficial influence of the blood components. The suppression 
of the MLR on day 5 post-transfusion by autologous blood supports previous 
findings that homologous blood transfusions suppress lymphocyte 
responsiveness (52). Over time, exposure to an unknown blood component(s) 
seems to contribute to a suppressed immune state. 
Since TfR has a role in T cell activation and iron absorption, TfR 
expression was examined by flow cytometry to determine if DST alters cell 
surface receptor expression. During the time of CTL suppression, DS1'-treated 
recipients exhibited a decrease in TfR cell surface expression in the total 
population of cells as well as on individual cells. Autologous blood also decreased 
TfR expression on day 3 post-transfusion, suggesting that blood component(s) 
were responsible and that the presence of alloantigen was irrelevant with 
regard to receptor expression. These studies are the first to demonstrate a 
possible link between reduced CTL responsiveness following DST and a 
decrease in TfR expression. DST- and autologous-treated recipients exhibited 
increases in CD3 and IL-2R expression. However, these increases were only in 
the total population of cells, since the mean channel fluorescence was not 
affected. This increase in CD3 and IL-2R expression indicates recruitment of 
CD3+ cells accompanied by activation. Despite the recruitment and partial 
activation, the decrease in TfR expression suggests that these cells fail to 
become fully activated. These results support the previously-mentioned 
conclusion that blood components(s) may be responsible for the alterations in 
receptor expression, since DST and autologous blood had similar effects on TfR, 
IL-2R, and CD3 expression. 
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As demonstrated in the CTL response, the effects of blood transfusions 
on receptor expression were also transient. On days 4 and 5 post-transfusion, 
DST and autologous blood had no effect on TfR. This restoration of TfR 
expression to background levels corresponds to the recovery in the CTL 
response. In addition, the recovery of the CTL response following DST is 
accompanied by increased numbers of IL-2R+ cells. This was also evident by 
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examination of TfR+IL-2R+ lymphocytes on day 4 and 5 post-transfusion. 
DST caused an increase in the number of fully activated T cells. These data 
suggest that the presence of alloantigen in the DST is activating and priming 
the CTLs to respond on days 4 and 5 post-transfusion, when the beneficial 
blood effect on TfR expression has been lost. 
These studies are the first to demonstrate a possible link between TfR 
expression and CTL suppression following DST. This suppression, despite an 
increase in CD3 and IL-2R, suggests that TfR expression has a powerful 
influence on CTL responsiveness. Since autologous-treated recipients 
demonstrated a decrease in TfR and a strong CTL response, the 
immunosuppression by DST was conditional on the presence of alloantigen. 
Whether the accompanying iron load by the blood transfusions 
contributes to this immunosuppression has yet to be proven. Good et ale 
demonstrated in mice that experimental iron-overload resulted in diminished 
alloantigen-specific CTL responses and a reduction in the number of IL .. 2-
secreting cells (124). In addition, several researchers have shown that the 
THI cytokines, IL-2 and INF-l', strongly enhance TfR expression (98, 99) 
Therefore, the reduction in IL-2-secreting cells in the experimental iron .. 
overload mice may have been associated with decreased TfR expression. This 
fact was not examined in this model. However, our observations suggest that 
suppression in the DST model may indeed be a result of the accompanying iron 
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load, requiring prior exposure to alloantigen. Future studies will be aimed at 
establishing the roles of iron, TfR, and alloantigen in the immunosuppression 
observed following DST. Understanding the mechanism(s) responsible for the 
immunosuppressive effects of DST may provide new immunosuppressive 




In clinical transplantation, the development of a potent, donor-specific, 
non-toxic immunosuppressive agent remains one of the major goals. Current 
immunosuppressants are global and nonspecific, leaving the patient 
susceptible to infections and to the harmful side effects. The discovery of an 
immunosuppressant regimen that is capable of specifically targeting T cells 
responding to the presence of alloantigen, while leaving the remainder of the 
immune system intact, would provide an ideal therapeutic regimen for clinical 
transplantation. 
TfR is a widely distributed cell surface receptor present on most rapidly 
proliferating and specialized quiescent cells that have particular needs for high 
levels of iron (2, 3). TfR functions in iron transport, cellular growth, and T cell 
activation. TfR expression increases following T cell activation after IL-2R 
expression (4, 14, 28). However, the roles and mechanisms of TfR in T cell 
activation remain ill-defined. Since the induction of TfR expression appears 
only after T cell activation, TfR would be a novel target on allo-reactive T cells 
following transplantation. 
With these concepts forming the basis of this dissertation, the overall 
objectives of this project were to understand the role(s) of transferrin receptor 
in T cell activation, and to define new immunosuppressive regimens for clinical 
transplantation. We examined the hypothesis that modulation of T cell 
transferrin receptor expression is associated with altered T cell responses to 
alloantigen. Specific Aim I examined the ability of anti-TfR mAb to act as an 
immunosuppressant in prolonging allograft survival and altering T cell 
responses to alloantigen. Anti-TfR mAb was most effective as an 
immunosuppressive regimen for allograft prolongation was during the time of 
antigen presentation. Specific Aim II explored the modulation of TfR 
expression during altered T cell responses. In vitro treatment with anti-CD3 
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mAb or anti-TfR mAb in combination with anti-IL-2R mAb decreased TfR 
expreSSIon. Modulation of TfR may contribute to the immunosuppressive 
effects of these agents. TfR modulation in association with the 
immunosuppressive effects of DST were demonstrated by a decrease in TfR 
expression which paralleled early CTL suppression. CTL recovery was 
correlated with normal levels of TfR. Specific Aim III delineated the 
mechanisms responsible for prolonged allograft survival and altered T cell 
responses to alloantigen by anti-TfR mAb. Alterations in the cytokine micro-
environment and signaling pathways, as well as modulation in expression of 
cell surface receptors important in T cell activation, seem to be responsible for 
generating T cell hyporesponsiveness mediated by anti-TfR mAb. The 
mechanisms may contribute to the prolonged cardiac allograft survival. 
Chapter 1 of this dissertation described the roles of TfR in iron 
absorption and T cell activation. A survey of the literature concerning TfR 
blockade and modulation in the area of cancer immunotherapy serves as the 
foundation from which the work presented here was built. 
Chapter 2 described the materials and methods utilized to approach the 
specific aims of this dissertation. To begin addressing the efficacy of TfR as a 
target in transplantation, a murine heterotopic, nonvascularized cardiac 
allograft model was utilized, which is a relatively simple technique to study 
allograft survival in vivo. T cell function and response assays were also used to 
detennine the effectiveness of TfR as a target. 
Chapter 3 of this dissertation described the effect of in V1,VO 
administration of anti-TfR mAb on allograft prolongation and examines the in 
vitro effects of anti-TfR mAb on cell-mediated immunity. These data revealed 
that administration of anti-TfR mAb at 100 Jlg on the day of transplantation 
and on the following day significantly prolonged cardiac allograft survival. Anti-
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TfR mAb was also effective in suppressing in vitro cytotoxic and proliferative T 
cells responses, suggesting that the mAb specific for TfR was a potent 
immunosuppressant. In addition, anti-TfR mAb may have contributed to the 
prolonged cardiac allograft survival by suppressing cell-mediated immune 
responses to alloantigen. Several mechanisms appeared to be involved in 
these altered T cell responses. One such mechanism involves alterations in 
important receptors involved in T cell activation. The mAb had enhanced 
activational properties that were demonstrated by increased populations of 
CD3, CD2B, and B7 expressing cells. In addition, anti-TfR mAb influenced the 
CD4ICDB T cell ratio in alloantigen-stimulated cultures. An increase in CD4+ 
T cells was accompanied by the lack of activation, as exhibited by a lack of IL-
2R expression. The remaining CD8+ T cells also lacked IL-2R expression. The 
inhibition of CD4+ T helper cell activation may have been responsible for the 
decrease in the number and inactivation of CD8+ T cells. The increased 
expression of CD3, CD28, and B7, and the association of TfR with CD3 zeta-
chain and ZAP70 following administration of anti-TfR mAb, suggest that TfR 
may play a role in the amplification of T cell activation. Co-
immunopreciptation experiments revealed that anti-TfR mAb failed to disrupt 
the physical association between TfR and CD3 zeta-chain or ZAP70 in 
activated or inactivated immortalized T cells. Despite this continued 
association, preliminary studies demonstrated that Tffi. blockade appears to 
affect the phosphorylation of ZAP70, while eD3 zeta-chain phosphorylation 
remains unchanged. Therefore, these findings supported the conclusion that 
interference with the signaling patterns generated by TfR may be the 
underlying mechanism responsible for alterations in receptor expression and 
suppressed T cell responses following anti-TfR mAb treatment. 
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To further define the effects of in vivo administration of anti-TfR mAb 
on allograft prolongation, Chapter 4 of this dissertation describes the effects of 
administration of anti-TfR mAb on days 2 and 3 and on days 0-3 post-
transplantation. Administration of anti-TfR mAb on days 2 and 3 post-
transplantation, at the time of maximal TfR expression, failed to prolong 
cardiac allograft survival. However, administration on days 0-3 during the 
time of antigen presentation and maximal TfR expression prolonged cardiac 
allograft survival. Administration of the mAb on days 0-3 was no more 
effective than administration of anti-TfR mAb on days 0 and 1, at the time of 
antigen presentation. These results demonstrate that TfR blockade at the 
time of antigen presentation and at the initiation of an immune response to the 
transplanted alloantigen was the most beneficial regimen for allograft 
prolongation. 
Several mechanisms appear to be responsible for the prolonged cardiac 
allograft survival following anti-TfR mAb treatment. Anti-TfR mAb 
suppressed the MLR to donor-specific and third party alloantigen. Alterations 
in intragraft cytokine mRNA expression and decreases in CD4 co-receptor and 
B7 ligands may contribute to allograft prolongation and altered T cell 
responses to alloantigen. The lack of long-term allograft survival in mice 
treated with anti-TfR mAb may be due to the lack of CTL suppression and the 
presence of INF-I'mRNA expression, both of which are indicative of an ongoing 
immune response. 
Since TfR expression follows the induction of IL-2R in a sequence that is 
necessary for initiating cell proliferation in quiescent T lymphocytes, it was 
important to determine if simultaneous administration of anti-TfR and anti-IL-
2R mAbs is a more effective regimen for prolonged allograft survival. In 
Chapter 5 of this dissertation, the efficacy of simultaneous blockade of TfR and 
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IL-2R was evaluated. Administration of anti-TfR and anti-IL-2R mAbs was 
more effective in prolonging allograft survival than was administration of 
either agent alone, suggesting that both TfR and IL-2R are important during 
alloantigen stimulation. Both receptors need to be blocked at the time of 
antigen presentation, antigen-specific T cell priming, and cell surface receptor 
up-regulation in order to achieve the most effective regimen of 
immunosuppression. Combination of anti-TfR and anti-IL-2R mAbs 
stimulated the CTL response to donor-specific and third party alloantigen in 
the allograft recipients, demonstrating that suppressed CTL function was not 
the primary mechanism involved in allograft prolongation. However, the 
combination decreased the T cell activation markers TfR and IL-2R at the 
time of antigen presentation and during an ongoing immune response, 
respectively. The combination was more effective at altering cytokine mRNA 
expression than either agent alone. Specifically, these agents down-regulated 
IL-2, INF-yand IL-15 mRNA expression, while simultaneously up-regulating 
IL-4 mRNA expression. Therefore, these immunosuppressive agents were 
effective in prolonging allograft survival by shifting the TH cytokine paradigm 
and altering T cell activation receptors. 
Several key studies in the laboratory utilizing various 
immunosuppressants have demonstrated prolonged cardiac allograft survival. 
Blocking the antigen-specific signal with anti-CD3 mAb alone led to short-term 
cardiac allograft survival (37) (Table 8), while blocking individual costimulatory 
signal with mAbs or fusion proteins specific for CD2, CD48, B7-1, or B7-2 
resulted in short-term to moderate cardiac allograft survival (37, 48, 49, 125) 
(Table 8). By interrupting TfR and/or IL-2R, short-term to moderate cardiac 
allograft survival was achieved (65, 73, 126, 127) (Table 8). Nevertheless, 
long-term allograft survival or tolerance was achieved by blocking multiple 
149 
receptors involved in T cell activation, such CD2 and CD3, CD48 and CD2 and 
B7 -1 and B7 -2 (37, 49, 128) (Table 8). 
Table 8. Summary of Allograft Prolongation Utilizing 
Various Immunosuppressants 
Transplant recipients Days of Treatment Mean Survival Time 
(post-transplant) (days) 
Untreated N/A 13.3 + 0.6 
Anti-CD2 mAb 100 ~g o and 1 24.8 + 1.0 
Anti-CD3 mAb 1 mg 0, 1, 2, 5, 10 27.4 ± 3.3 
Anti-CD4 mAb 100 Jlg o and 1 20.0 + 1.0 
Anti-CD48 mAb 100 Jlg o and 1 19.9 ± 0.6 
Anti-C02 mAb 100 Jlg/Anti-CD3 mAb 1 mg o and 110t 1, 2, 5, 10 35.8 + 0.7 
Anti-C02 mAb 100 ~glAnti-CD3 mAb 1 rng o and 1/2, 3, 4, 5, 10 >150.0 
Anti-C02 mAb/Anti-CD4 mAb 100 ~g o and 1 22.8 ± 3.1 
Anti-CD2 mAbl Anti-CD48 mAb 100 Jlg o and 1 >100.0 
CTLA4Ig 100 )lg o and 1 55.0 ± 2.0 
Anti-CD2 mAb/CfLA4Ig 100 Jlg o and 1 >120.0 
Anti-B7-1 mAb 100 ~g o and 1 29.8 + 1.5 
Anti-B7-2 mAb 100 ~g o and 1 30.8 + 0.5 
Anti-B7-1 mAb/Anti-B7-2 mAb 100 Jlg o and 1 51.4 ± 9.0 
Anti-B7-2 mAb/Anti-B7-1 rnAb 100 Jlg o and 1/2 and 3 >90.0 
Anti-TfR mAb 100 Jlg o and 1 25.7 + 0.9 
Anti-TfR mAb 100 Jlg 2 and 3 13.0 + 0.0 
Anti-TfR mAb 100 Jlg o through 3 20.3 + 1.5 
Anti-IL-2R mAb 100 ~g o and 1 12.5 + 0.9 
Anti-IL-2R mAb 50 Jlg o through 5 23.5 ± 6.6 
Anti-IL-2R mAb 100 Jlg o through 5 47.0 + 3.8 
Anti-TtRlAnti-IL-2R 100 J.Lg o and 1 50.7 + 2.0 
Neonatal C57BU6 donor hearts were placed subcutaneously in the ear pinnae 
of adult CBAlJ recipients, receiving intravenous injections of the 
immunosuppressant(s) at the indicated dose(s) and days. Allograft survival 
was determined by EKG monitoring. 
Chapter 6 of this dissertation explored the modulation ofTfR expression 
during altered T cell responses to alloantigen. Anti-CD3 mAb, CTLA4Ig, and 
anti-IL-2R mAb interrupt signals that occur prior to the expression of TfR 
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during T cell activation. These current immunosuppressants, which are 
specific for each of the steps involved in T cell activation prior to TfR 
expression, were utilized to examine receptor modulation and to suggest 
possible roles for TfR in T cell activation. Previous results in the laboratory 
demonstrated that in vitro treatment with anti-TfR mAb suppresses cytotoxic 
and proliferative T cell responses. The studies described here revealed that in 
vitro treatment with anti-CD3 mAb, or with anti-TfR mAb alone or in 
combination with anti-IL-2R mAb, down-regulated TfR expression, while anti-
IL-2R mAb alone had no effect on TfR expression. Furthermore, CTLA4Ig had 
no effect on TfR expression. The down-modulation of TfR by anti-CD3 mAb 
may be due to the physical association of TfR and CD3 zeta-chain, since 
simultaneous reduction in CD3 and TfR expression was observed. These data 
suggest that TfR plays an early role in T cell activation. TfR alterations 
induced by these mAbs may contribute to the suppressed T cell responses to 
alloantigen. In addition, these studies demonstrated that the induction ofTfR 
expression was independent of CD28 and IL-2R signaling, while CD3 signaling 
was involved in the promotion ofTfR expression. Thus, these studies defined 
possible roles ofTfR in T cell activation. 
Since TfR has dual roles in iron absorption and T cell activation, 
Chapter 7 of this dissertation examined the immunosuppressive effects of DST 
in relation to altered function and regulation of TfR in T cell activation and 
allograft rejection. Time course experiments were performed to assess T cell 
responsiveness and TfR expression following administration of DST. 
Administration of DST significantly suppressed the CTL response, while 
autologous blood had no effect on day 3 post-transfusion. These results 
suggest that the immunosuppression generated by DST depends on the 
presence of alloantigen. At the time of CTL suppression, DST decreased the 
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population of TfR-expressing cells, suggesting that TfR expression has a 
powerful influence on CTL responsiveness. However, CTL suppression was 
transient, since continued exposure to DST resulted in stimulation of the CTL 
response followed by a recovery in Tffi expression. Therefore, a continued 
immunosuppressive effect by DST may require the administration of DST in 
combination with CWTent immunosuppressive agents such as azathioprine or 
cyclosporin A. These studies were the first to demonstrate a possible link 
between TfR expression and CTL suppression following DST. 
Future directions in this area of research are many. Further 
examination of the graft site is necessary to better understand the roles ofTfR 
in T cell activation and function. This can be accomplished by characterizing 
the graft-infiltrating cell through use of immunohistochemistry and flow 
cytometry. Limiting dilution analyses will determine the proportion of 
lymphocytes able to perform CTL effector responses. In addition, RT-PCR can 
be utilized to determine CTL involvement at the graft site. The signaling 
pathways of TfR have not been well defined. TfR signaling has been shown to 
be calcium dependent. Therefore, TfR may share some signaling pathways 
with the TCRlCD3. Describing the pathways that are unique to the role ofTfR 
in T cell activation rather than iron absorption, and delineating the importance 
of these pathways in T cell activation may lead to the development of new 
therapeutic regimens for clinical transplantation. 
The results of these investigations have clarified and enhanced previous 
reports that TfR is not simply an iron transporter, but is an important and 
independent receptor in T cell activation. Anti-TfR mAb is a potent 
immunosuppressant prolonging cardiac allograft survival, altering cell surface 
receptors important in T cell activation, shifting intragraft cytokine profiles, 
affecting signaling pathways, and suppressing T cell proliferation. The 
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experimental transplant model used in these studies does have limitations. 
This model does not directly mimic vascularized transplants, and the lack of 
vascularization leads to delayed immune responses. However, this model does 
provide a simple in vivo technique to examine the possible therapeutic use of 
new immunosuppressive agents. Achieving immunosuppression with a short 
course of mAbs would have beneficial ramifications for the transplant patient, 
since current immunosuppressive agents require long-term usage, often 
resulting in a higher occurrence of infections and malignancies. Enhanced 
cardiac allograft survival can be achieved with simultaneous blockade of TfR 
and IL .. 2R. The novel blockade ofTfR alone or in combination with IL .. 2R in 
the transplant and cell-mediated immunity models have provided additional 
insights into the development of better immunosuppressive regimens for 
clinical transplantation. The use of anti-TfR mAb as a therapeutic regimen in 
clinical transplantation may require the administration of the mAb in 
combination with current immunosuppressive agents such as azathioprine or 
cyclosporin A. 
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